<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment</title>
				<funder ref="#_fTwUxVd">
					<orgName type="full">Natural Science Foundation of Chongqing</orgName>
				</funder>
				<funder ref="#_2B9J2P8">
					<orgName type="full">Major International (Regional)</orgName>
				</funder>
				<funder ref="#_KVGSb5N #_YK6rdn9">
					<orgName type="full">National Natural Science Foundation of China</orgName>
				</funder>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2024-02-13">13 February 2024</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Yijiao</forename><surname>Chen</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Yongsheng</forename><surname>Li</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Lei</forename><surname>Wu</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Anushka</forename><surname>Dongre</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Wei</forename><surname>Yang</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Daniele</forename><surname>Vergara</surname></persName>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Medical Oncology</orgName>
								<orgName type="department" key="dep2">School of Medicine</orgName>
								<orgName type="institution">Chongqing University Cancer Hospital</orgName>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="institution">Chongqing University</orgName>
								<address>
									<settlement>Chongqing</settlement>
									<country key="CN">China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="institution">Cornell University</orgName>
								<address>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="institution">Stony Brook University</orgName>
								<address>
									<country key="US">United States</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="institution">University of Salento</orgName>
								<address>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Protein S-palmitoylation modification: implications in tumor and tumor immune microenvironment</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2024-02-13">13 February 2024</date>
						</imprint>
					</monogr>
					<idno type="MD5">1BC24484D6EB83497C48FBC437C74622</idno>
					<idno type="DOI">10.3389/fimmu.2024.1337478</idno>
					<note type="submission">RECEIVED 13 November 2023 ACCEPTED 29 January 2024</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.8.0" ident="GROBID" when="2024-05-25T07:16+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>protein S-palmitoylation</term>
					<term>lipid modification</term>
					<term>tumor cells</term>
					<term>tumor immune microenvironment</term>
					<term>immunotherapeutic strategies</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>Protein S-palmitoylation is a reversible post-translational lipid modification that involves the addition of a 16-carbon palmitoyl group to a protein cysteine residue via a thioester linkage. This modification plays a crucial role in the regulation protein localization, accumulation, secretion, stability, and function. Dysregulation of protein S-palmitoylation can disrupt cellular pathways and contribute to the development of various diseases, particularly cancers. Aberrant S-palmitoylation has been extensively studied and proven to be involved in tumor initiation and growth, metastasis, and apoptosis. In addition, emerging evidence suggests that protein S-palmitoylation may also have a potential role in immune modulation. Therefore, a comprehensive understanding of the regulatory mechanisms of S-palmitoylation in tumor cells and the tumor immune microenvironment is essential to improve our understanding of this process. In this review, we summarize the recent progress of S-palmitoylation in tumors and the tumor immune microenvironment, focusing on the S-palmitoylation modification of various proteins. Furthermore, we propose new ideas for immunotherapeutic strategies through S-palmitoylation intervention.</p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="1">Introduction</head><p>S-palmitoylation is a highly conserved post-translational lipid modification of proteins that is widely present in eukaryotes. It plays a crucial role in various physiological processes by influencing protein structure, localization, transport, and function <ref type="bibr" target="#b0">(1)</ref>. Recent systemlevel analysis has revealed that S-palmitoylation affects more than 10% of the proteome, estimating that there are nearly 1,000 palmitoylated proteins in humans <ref type="bibr" target="#b1">(2)</ref>. Protein palmitoylation can be categorized into S-palmitoylation, Npalmitoylation, and O-palmitoylation based on the different acyl receptors <ref type="bibr" target="#b2">(3)</ref>. Among these modification, S-palmitoylation occurs on cysteine residue of a protein, involves a thioester linkage and is a reversible modification. N-palmitoylation can occur at both the Nterminus and the epsilon amino group of the protein via an amide bond. O-palmitoylation involves the attachment of palmitate to the serine and threonine residues of target protein via an ester bond (4). S-palmitoylated proteins are mainly membrane proteins, particularly transmembrane proteins and peripheral membrane proteins <ref type="bibr" target="#b4">(5)</ref>. The S-palmitoylation modification increases protein hydrophobicity and membrane binding ability, thereby altering protein structure, localization, transport, and function.</p><p>Protein S-palmitoylation plays an important role in tumor progression as many oncogenic proteins or tumor suppressors are palmitoylated <ref type="bibr" target="#b6">(6)</ref>. Recent studies have shown that protein S-palmitoylation in tumor cells or immune cells influences the tumor immune microenvironment by regulating the activation, depletion, and infiltration of immune cells <ref type="bibr" target="#b7">(7,</ref><ref type="bibr" target="#b8">8)</ref>. The emergence of multiple immune checkpoint inhibitors and the success of various tumor immunotherapy clinical trials have greatly contributed to the advancement of tumor immunotherapy <ref type="bibr" target="#b9">(9,</ref><ref type="bibr" target="#b10">10)</ref>. Understanding the impact of protein S-palmitoylation on the tumor immune microenvironment is a key area of research in this field. This review provides a comprehensive analysis of how S-palmitoylation regulates tumor cells and the tumor immune microenvironment. Furthermore, it explores potential ideas for more precise personalized treatment through the development of protein S-palmitoylation targeted drugs.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="2">Dynamic regulation of protein S-palmitoylation</head><p>Unlike other permanent lipid attachments, S-palmitoylation can be reversed by cellular thioesterases, allowing for dynamic regulation of the local hydrophobicity of substrate proteins <ref type="bibr" target="#b11">(11)</ref>. Protein Spalmitoylation is catalyzed by palmitoyl S-acyltransferases (PATs) and acyl-protein thioesterases (APTs) enzymes (Figure <ref type="figure">1</ref>) <ref type="bibr" target="#b3">(4)</ref>. Proteins can transition between palmitoylated and de-palmitoylated forms within timeframes ranging from seconds to hours <ref type="bibr" target="#b12">(12)</ref>. The dynamic process of S-palmitoylation can impact protein localization, accumulation, secretion, stability, and function by altering membrane affinity <ref type="bibr" target="#b13">(13)</ref>. Investigating how protein S-palmitoylation influences the function of specific proteins in both normal and cancer cells is a significant driving force behind current research in this field.</p><p>In humans, S-palmitoylation is catalyzed by a family of zinc finger and DHHC motif-containing palmitoyl acyltransferases (zDHHC-PATs). The zDHHC proteins have four to six transmembrane domains contain a signature Asp-His-His-Cys (DHHC) motif within the cysteine-rich domain in the intracellular loop <ref type="bibr" target="#b13">(13,</ref><ref type="bibr" target="#b14">14)</ref>. The majority of zDHHC proteins are localized in the endoplasmic reticulum (ER) and Golgi apparatus, which are the primary sites of protein S-palmitoylation activity in mammalian cells (Table <ref type="table" target="#tab_0">1</ref>). The crystal structure analysis of human zDHHC20 has confirmed that the transfer of palmitoyl-CoA to substrate occurs in two steps <ref type="bibr" target="#b15">(15,</ref><ref type="bibr" target="#b16">16)</ref>. zDHHC20 exhibits a teepee-like structure, wider at the cytoplasmic side and narrower at the membrane-inner side, with the DHHC active site positioned at the cytoplasmic junction between the transmembrane domains 2 and 3 <ref type="bibr" target="#b12">(12)</ref>. This position</p><formula xml:id="formula_0">A B FIGURE 1</formula><p>The reversible palmitoylation of proteins mediated by the enzymes zDHHC1 and APT1. (A) The molecular structures of human palmitoyltransferase zDHHC1 (predicted by SWISS-MODEL) and its substrate P53 (PDB ID: 1uol) are depicted. zDHHC-PATs are membrane proteins that contain 4 or 6 transmembrane domains. The enzyme's catalytic DHHC motif is located in the cytoplasm. During the S-palmitoylation process, the DHHC domain of zDHHCs binds to palmitoyl-CoA and undergoes autopalmitoylation. Subsequently, the palmitate group is transferred to the cysteine residue of the substrate protein, thereby promoting the membrane localization of the substrates. (B) The molecular structures of human APT1 (PDB ID: 5sym) and its substrate protein HRAS (PDB ID: 1agp) are depicted. APT1 removes palmitic acid groups from the palmitoylated substrate. APT1/2 itself undergoes palmitoacylation and contains a hydrophobic pocket to accept the palmitoacylated substrates and hydrolyze them.    </p><p>allows for interaction with both palmitoyl-CoA and substrate proteins at the membrane-cytosol interface. Palmitoyl-CoA first reacts with the cysteine residue in the DHHC motif, forming an acyl-intermediate and releasing free CoA-SH <ref type="bibr" target="#b12">(12)</ref>. Subsequently, this intermediate is transferred from the DHHC motif to the substrate proteins directly. Cysteine residues located near the catalytic DHHC motif coordinate two structural zinc atoms that are vital for the proper folding and function of the enzyme, but do not play a catalytic role in palmitic acid transfer <ref type="bibr" target="#b17">(17)</ref>. Despite sharing similar amino acid sequences, the 24 human zDHHC enzymes exhibit distinct abilities for self-acylation, indicating their diverse roles in tumor progression <ref type="bibr" target="#b18">(18)</ref>. It should be emphasized that although palmitate (C16:0) is the main lipid of endogenous S-acylated proteins, other fatty acids such as stearate (C18:0) and oleate (C18:1) can also be added to a protein cysteine residue <ref type="bibr" target="#b19">(19)</ref>. In addition, different cell types may exhibit different S-acylated lipid profiles, and in fact, the lipid profiles of S-acylated proteins in cells have been reported to be significantly influenced by the lipid composition of the extracellular environment <ref type="bibr" target="#b19">(19)</ref>. Since there is no consistent S-palmitoylation sequence, how the zDHHC enzyme selects specific substrate proteins for modification is not fully understood. S-palmitoylation proteins can usually be catalyzed by more than one zDHHC enzyme, but a specific zDHHC enzyme is usually more potent than other enzymes for the substrate palmitoylation in cells <ref type="bibr" target="#b18">(18)</ref>. Interestingly, certain zDHHC enzymes have unique substrate binding preferences. For some proteins, proteins palmitoylation requires other lipidation events to occur on amino acid residues close to palmitoylated Cys residues (e.g., RAS farnesylation, SRC family myristoylation), and these modifications help substrate locate to zDHHC-enriched membrane region <ref type="bibr" target="#b20">(20)</ref>. zDHHC13 and zDHHC17 contain unique C-terminal ankyloprotein repeat domains that bind certain  substrate and enhance their membrane localization, promoting substrate S-palmitoylation by other zDHHC enzymes <ref type="bibr" target="#b18">(18)</ref>. In addition, the palmitoylation process of some zDHHC enzymes such as zDHHC9 and zDHHC6 requires the involvement of a helper protein such as Selenoprotein K <ref type="bibr" target="#b21">(21)</ref>. Therefore, these helper proteins may contribute to substrate selection. For some protein substrates, only certain portions of cysteine residues can be S-palmitoacylated. Progress has been made in computational prediction, but experiments are still needed to determine which specific cysteines in proteins will be modified. It was found that S-palmitoylation of membrane proteins preferentially occurs at cysteine located in the 8 angstroms range of the membranecytoplasmic interface, which provides a structural constraint on the S-palmitoylation potential of certain residues of the substrate protein <ref type="bibr" target="#b22">(22)</ref>. These results suggest that further studies are needed to determine how substrate conformation or binding affects protein S-palmitoylation. Depalmitoylation modification in mammalian cells is catalyzed by APTs and palmitoyl-protein thioesterases (PPTs), as well as the mammalian a/b hydrolase domain-containing proteins (ABHDs) (Table <ref type="table" target="#tab_6">2</ref>) <ref type="bibr" target="#b23">(23)</ref>. Soluble APT2 weakly interacts with the cell membrane through its b tongue. It can separate from the membrane or encounter zDHHC3/7 <ref type="bibr" target="#b24">(24)</ref>. In this case, zDHHC3/ 7 mediates APT2 S-palmitoylation at Cys2, allowing APT2 to stably bind to the membrane and search for potential substrates <ref type="bibr" target="#b25">(25)</ref>. When APT2 encounters a substrate, it triggers the extraction of an acyl chain from the membrane, causing it to move into the APT2 hydrophobic pocket. With this ideal positioning, APT2 hydrolyzes the substrates (26). Interestingly, inhibiting APT1 expression or its thioesterase activity markedly increases the membrane localization of APT2, while shRNA suppression of APT2 has no effect on the membrane localization of APT1 <ref type="bibr" target="#b26">(27)</ref>. These results indicate that APT1 and APT2 S-palmitoylation link cytosol-membrane trafficking of their substrates, facilitating their membrane localization and function. PPT1 plays a critical role in protein depalmitoylation. However, the substrates of PPT1 and the catalytic process are largely unknown. A recent study used a 2-step proteomic approach to identify 138 novel PPT1 substrates <ref type="bibr" target="#b27">(28)</ref>. They found that the validated substrates of PPT1 frequently catalyze cysteine residues that participate in disulfide bonds. The depalmitoylated cysteines catalyzed by PPT1 spontaneously form disulfide bonds in the oxidative environment, suggesting a novel function of PPT1 in oxidative stress. ABHD17A, ABHD17B, and ABHD17C are novel depalmitoylation enzymes that have been recently identified as regulators of N-Ras, Psd-95, and MAP6 depalmitoylation <ref type="bibr" target="#b28">(29,</ref><ref type="bibr" target="#b29">30)</ref>. N-Ras depalmitoylation by ABHD17 is required for its re-localization to internal cellular membranes <ref type="bibr" target="#b30">(31)</ref>.</p><p>Palmitoyl proteins play a crucial role in complex regulatory networks. For instance, zDHHC5, zDHHC6, and zDHHC8 are responsible for catalyzing the S-palmitoylation of cysteine residues that are located outside the DHHC motif. These modifications are essential for ensuring the proper localization and functioning of the enzyme <ref type="bibr" target="#b12">(12)</ref>. Recent research has demonstrated that zDHHC16 physically interacts with zDHHC6 and palmitoylates the Cys328, Cys329, and Cys343 residues of the C-terminal Src Homology 3 (SH3) domain of zDHHC6 <ref type="bibr" target="#b31">(32)</ref>. The S-palmitoylation of zDHHC6 by zDHHC16 enhances the overall stability and activity of zDHHC6. However, it is important to note that different configurations of modifications yield varying activity and stability profiles. The S-palmitoylation of zDHHC6 on these C-terminal cysteine residues is reversible through APT2, with the conversion occurring particularly rapidly at Cys328. The thioesterases belonging to the APT1/2 and ABHD families are also palmitoylated, and this modification is crucial for their proper localization and functioning <ref type="bibr" target="#b25">(25)</ref>. PPT1 is another protein that undergoes S-palmitoylation by zDHHC3 and zDHHC7, although in this case, S-palmitoylation reduces enzyme activity. Moreover, both the PAT enzymes (e.g., zDHHC3, zDHHC13) and the APT enzymes (e.g., APT1, APT2) can be regulated through phosphorylation or ubiquitination in cancer and other cells, further adding to the complexity of this regulatory network. Thus, a complex web of interconnected modifications regulates the localization and functioning of both zDHHC and thioesterase proteins, which has significant implications for the regulation of cancer-associated proteins.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3">Proteins S-palmitoylation in cancer</head><p>Protein S-palmitoylation plays a crucial role in cancer initiation, cancer cell growth, survival, and modulation of the anti-tumor immune response. Aberrant S-palmitoylation of proteins may indicate functional alterations in cancer. Several studies have demonstrated that the zDHHC family members can both inhibit and promote tumorigenicity by regulating S-palmitoylation of important proteins, including epidermal growth factor receptor (EGFR), Ras, and PD-L1, etc. <ref type="bibr" target="#b32">(33,</ref><ref type="bibr" target="#b33">34)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.1">Protein S-palmitoylation in the regulation of oncogenic or tumorsuppressive signaling</head><p>Numerous carcinogenic or tumor-suppressive proteins involved in tumorigenesis, metastasis, or drug resistance are regulated by S-palmitoylation. Studies have shown that zDHHC9mediated S-palmitoylation of oncogenic NRAS is essential for its localization on the plasma membranes and downstream signaling activation, promoting the occurrence of leukemia <ref type="bibr" target="#b33">(34,</ref><ref type="bibr" target="#b34">35)</ref>. APT1 has been found to depalmitoylate H-Ras and N-Ras, reducing their affinity to the plasma membrane and releasing them from it, allowing diffusion back into the Golgi apparatus <ref type="bibr" target="#b35">(36,</ref><ref type="bibr" target="#b36">37)</ref>. Therefore, the S-palmitoylation-depalmitoylation cycle of N-Ras and H-Ras regulates the transport of Ras between the Golgi apparatus and the plasma membrane (Figure <ref type="figure">2</ref>). EGFR, a growth factor receptor critical for cell proliferation and differentiation <ref type="bibr" target="#b37">(38)</ref>, S-palmitoylation of EGFR by zDHHC1, zDHHC2, and/or zDHHC21 on Cys797 is essential for the stability, membrane localization, dimerization, and activation of this receptor and increases cell migration and anchor-independent growth in lung cancer <ref type="bibr" target="#b38">(39)</ref>. Fatty acid synthase (FASN), a major lipogenic enzyme that synthesizes palmitic acid <ref type="bibr" target="#b39">(40)</ref>, induces an oncogenic phenotype when overexpressed in normal cells. This transformation involves enhanced lipid synthesis and an increase in phosphorylation and expression of EGFR <ref type="bibr" target="#b40">(41)</ref>. EGFR activation is involved in FASNdependent palmitoylation, which is required for both liganddependent and ligand-independent activation of EGFR and</p><formula xml:id="formula_2">A B D C FIGURE 2</formula><p>The functional roles of protein S-palmitoylation in cancer. Palmitoylation regulates oncogenic or tumor-suppressive signaling pathways (A), apoptosis (B), tumor metastasis (C) and tumor metabolism (D).</p><p>occurs within the cell. Treatment of prostate and lung cancer cells with the FASN inhibitor cerulenin or the palmitoylation inhibitor 2-bromopalmitate (2-BP) reduces EGFR levels on the plasma membrane while increasing lysosome levels <ref type="bibr" target="#b41">(42)</ref>. A recent published study also reported the lipid-rich microenvironment activates palmitate biosynthesis in metastatic colorectal cancer cells by up-regulating FASN. The increased intracellular palmitate promotes EGFR palmitoylation, thereby activating EGFR signaling. The FASN inhibitor orlistat inhibits EGFR palmitoylation and inhibits the stem cell properties of colorectal cancer (CRC) cells <ref type="bibr" target="#b42">(43)</ref>. EGF stimulates the S-palmitoylation of the oncogenic protein CDCP1, thereby blocking the degradation of CDCP1 <ref type="bibr" target="#b43">(44)</ref>. This study establishes a connection between S-palmitoylation events and EGFR signaling. However, further research is required to fully understand the specific mechanisms involved.</p><p>The membrane protein claudin-3 (CLDN3) is crucial for the formation and maintenance of tight junctions and is highly expressed in various cancers <ref type="bibr" target="#b44">(45)</ref>. In ovarian cancer, zDHHC12 mediates S-palmitoylation of CLDN3 at C181, C182, and C184, which contributes to its proper localization and stabilization on the plasma membrane. zDHHC22 is significantly upregulated in renal cancer cells (RCC) resistant to tyrosine kinase inhibitors <ref type="bibr" target="#b45">(46)</ref>. In RCC, zDHHC2 mediates AGK S-palmitoylation, facilitating AGK translocation to the plasma membrane and activating the PI3K-AKT-mTOR signaling pathway <ref type="bibr" target="#b46">(47)</ref>. These findings indicate the existence of a zDHHC2-AGK signaling axis and suggest that targeting zDHHC2 could enhance the effectiveness of sunitinib in RCC treatment <ref type="bibr" target="#b46">(47)</ref>. zDHHC22 expression is significantly reduced in estrogen receptor-negative breast cancer tissues, and its expression is positively correlated with the clinical prognosis of breast cancer patients <ref type="bibr" target="#b45">(46)</ref>. Through S-palmitoylation, zDHHC22 decreases mTOR stability and suppresses AKT signaling pathway activation. Restoring zDHHC22 expression sensitizes tamoxifenresistant MCF-7 cells to tamoxifen treatment <ref type="bibr" target="#b45">(46)</ref>. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a crucial role in cholesterol metabolism and antitumor immune responses <ref type="bibr" target="#b47">(48)</ref>. Abnormal upregulation of PCSK9 promotes cell proliferation and sorafenib resistance in HCC. zDHHC16-mediated S-palmitoylation of PCSK9 at cysteine 600 enhances the binding affinity between PCSK9 and tensin homolog (PTEN) (49). Spalmitoylation of PCSK9 leads to lysosome-mediated PTEN degradation and subsequent AKT activation <ref type="bibr" target="#b48">(50)</ref>. Inhibiting PCSK9 S-palmitoylation suppresses AKT phosphorylation and enhances the antitumor effects of sorafenib (49).</p><p>P53 is a well-known tumor suppressor that regulates cell proliferation and apoptosis. The S-palmitoylation of p53 at the C135, C176, and C275 residues, mediated by zDHHC1, has been reported to play necessary roles in p53 nuclear trafficking and subsequent pathway activation (Figure <ref type="figure">1A</ref>) <ref type="bibr" target="#b49">(51)</ref>. Conversely, p53 epigenetically regulates zDHHC1 expression by recruiting DNMT3A and HDAC1 to the promoter region <ref type="bibr" target="#b49">(51)</ref>. This regulatory feedback loop could help explain the function of zDHHC family members and may be utilized for targeted therapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.2">S-palmitoylation and apoptosis</head><p>Apoptosis, a cell-intrinsic mechanism for suicide, plays a pivotal role in inflammatory diseases and tumors <ref type="bibr" target="#b50">(52)</ref>. Recent studies have identified dysregulated S-palmitoylation of apoptosis-related proteins in many human cancers. For instance, the TNF family receptor Fas can undergo S-palmitoylation, as revealed by metabolic labeling of [3H] palmitate in HEK293 cells <ref type="bibr" target="#b51">(53,</ref><ref type="bibr" target="#b52">54)</ref>. zDHHC7mediated S-palmitoylation of Fas leads to an increase in the active form of caspase-8 <ref type="bibr" target="#b53">(55)</ref>. Decreased expression of zDHHC7 inhibits the expression of Fas in the plasma membrane of SW480 cells, thereby suppressing FASL-induced apoptosis. While Fas is located on various cell surfaces, Fas ligand (FasL) is primarily found on activated T cells and natural killer (NK) cells <ref type="bibr" target="#b54">(56)</ref>. Dysregulation of Fas/FasL signaling compromises immune function. FasL can be palmitoylated at residue cysteine 82, and mutants at this site show significantly lower cell death compared to controls <ref type="bibr" target="#b55">(57)</ref>. S-palmitoylation of the Fas signaling member Lck is essential for Fas-mediated apoptosis <ref type="bibr" target="#b56">(58)</ref>. The binding of the Fas receptor to its ligand Fas results in a rapid and substantial increase in the S-palmitoylation level of the tyrosine kinase Lck. Inhibition of Lck S-palmitoylation not only disrupts proximal Fas signal transduction events but also confers resistance to Fas-mediated apoptosis. zDHHC21, a palmitoyltransferase, functions as a PAT that controls Lck activation. Knockout of zDHHC21 eliminates the activation and downstream signaling of Lck following Fas receptor stimulation <ref type="bibr" target="#b57">(59)</ref>.</p><p>Death receptor-6 (DR6) is a newly discovered member of the Death receptor subfamily that can induce apoptosis and/or activate NF-kB and JNK/SAPK family stress kinases in specific cell types <ref type="bibr" target="#b58">(60)</ref>. The S-palmitoylation of DR6 occurs at Cys368, but the relationship between DR6 S-palmitoylation and apoptosis requires further investigation. In COS7 cells, the increase in caspase-6 S-palmitoylation at the C264 and C277 sites, mediated by zDHHC17, leads to a decrease in caspase-6 activation (61). Additionally, S-palmitoylation can also occur in Bcl-2 family proapoptotic proteins. S-S-palmitoylation of BAX at Cys-126 is crucial for the apoptosis process as it affects its localization to the mitochondria <ref type="bibr" target="#b60">(62)</ref>. The mutation C126 significantly reduces the number of apoptotic cells and the activation of caspase-3. These findings collectively indicate that S-palmitoylation plays an essential role in the apoptosis process of immune cells and tumor cells.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.3">S-palmitoylation and tumor metastasis</head><p>Aberrant S-palmitoylation has been shown to contribute to tumor initiation and growth, and its potential role in tumor metastasis has been investigated. Tetraspanins, which are small membrane proteins, have been found to promote the adhesion and metastasis of tumor cells <ref type="bibr" target="#b61">(63)</ref>. The S-palmitoylation of integrin subunits beta-4 (ITGB4), alpha-3 (ITGA3), and alpha-6 (ITGA6) has an impact on the formation of integrin tetraspanin complexes <ref type="bibr" target="#b62">(64)</ref>. Additionally, ITGA6 and ITGB4 collaborate with EGFR and ERBB2 to promote various aspects of tumor progression and metastasis <ref type="bibr" target="#b63">(65)</ref>. It is crucial to conduct studies to determine how different S-palmitoylation of proteins interferes with EGF receptorintegrin dynamics within tetraspanin complexes. Ras-related protein RAB27A is significantly overexpressed in oral squamous cell carcinoma <ref type="bibr" target="#b64">(66)</ref>. RAB27A regulates the S-palmitoylation of EGFR via zDHHC13 in oral squamous cell carcinoma <ref type="bibr" target="#b64">(66)</ref>. The laminin-binding integrin a6b4 plays a key role during tumor cell metastasis <ref type="bibr" target="#b65">(67)</ref>.</p><p>Several studies have indicated that the S-palmitoylation of a6b4 protein by zDHHC3 inhibits the degradation of a6b4. This inhibition is likely due to a decrease in endosomal exposure to cathepsin D <ref type="bibr" target="#b66">(68)</ref>. Flotillin-1 is a membrane-associated protein that plays a role in multi-cellular signaling events in cells <ref type="bibr" target="#b67">(69)</ref>. It has been observed that Flotillin-1 is overexpressed in numerous solid tumors, and its S-palmitoylation contributes to its stability and subsequent metastatic capabilities in breast cancer cells and experimental metastasis models <ref type="bibr" target="#b68">(70,</ref><ref type="bibr" target="#b69">71)</ref>. Therefore, targeting flotillin-1 S-palmitoylation could be a promising approach for addressing breast cancer metastasis. MUC1, a mucin-like protein located on the apical membrane of epithelial cells, is also associated with tumor metastasis <ref type="bibr" target="#b70">(72)</ref>. S-palmitoylation of MUC1 modulates its recycling from endosomes to the plasma membrane (73), and the intracellular localization of MUC1 is altered during breast cancer metastasis <ref type="bibr" target="#b71">(74)</ref>. CCR5 is a CC chemokine receptor expressed on immune cells such as memory lymphocytes, macrophages, and dendritic cells. Weinberg and colleagues have discovered that CCR5 undergoes S-palmitoylation at three cysteine residues within its C-terminal region (75). Palmitoylated cysteines are known to have a significant role in the intracellular trafficking of CCR5. When CCR5 S-palmitoylation is eliminated, it reduces the surface expression of CCR5 by trapping the receptor in organelles, leading to its degradation. This is particularly relevant in breast cancer metastasis to bone, as CCR5 S-palmitoylation facilitates tumor metastatic spread through CCL5-CCR5 chemokine signaling. Another important factor in tumor metastasis is SMAD3, which is involved in the activation of the transforming growth factor-beta (TGF-b) signaling pathway <ref type="bibr" target="#b72">(76)</ref>. S-palmitoylation of SMAD3, mediated by palmitoyltransferase zDHHC19, promotes its activation. Furthermore, the interaction between SMAD3 and EP300 promotes the expression of mesenchymal markers in the mesenchymal subtype of glioblastoma multiforme (GBM). Therefore, targeting Smad3 S-palmitoylation could be a crucial molecular approach in combating tumor metastasis (77).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="3.4">Protein S-palmitoylation in the metabolic adaptation of tumors</head><p>The relationship between cellular metabolic reprogramming and protein S-palmitoylation is inherently connected, as Spalmitoylation involves the covalent attachment of palmitic acid to proteins. In cancer cells, the addition of the saturated fatty acid palmitate enhances the synthesis of palmitoyl-CoA, thereby upregulating protein S-palmitoylation <ref type="bibr" target="#b74">(78)</ref>. This direct involvement of central metabolites in post-translational modifications allows tumor cells to integrate information from the microenvironment and effectively regulate cellular processes. Consequently, these palmitoylated metabolic proteins are believed to influence cancer cell metabolism. For instance, glucose transporter (GLUT1), a transmembrane protein responsible for glucose uptake, is frequently upregulated in various cancer types <ref type="bibr" target="#b75">(79)</ref>. The localization of GLUT1 to the plasma membrane is crucial for its function in glucose uptake. Studies have shown that zDHHC9 mediates the S-palmitoylation of GLUT1 at C207, promoting its plasma membrane localization and resulting in heightened glycolysis in glioblastoma (80). Malate Dehydrogenase (MDH2), a key enzyme in the TCA cycle, catalyzes the reversible conversion of malate to oxaloacetate. S-palmitoylation of MDH2 by zDHHC18 at C138 leads to increased MDH2 activity <ref type="bibr" target="#b76">(81)</ref>. This S-palmitoylation event activates mitochondrial respiration and promotes the malignancy of ovarian cancer. Additionally, zDHHC21 has recently been identified as a critical regulator of oxidative phosphorylation activation in acute myeloid leukemia cells. zDHHC21 specifically catalyzes the S-palmitoylation of mitochondrial adenylate kinase 2 (AK2) and activates OXPHOS in these leukemia cells <ref type="bibr" target="#b77">(82)</ref>. Depletion of ZDHHC21 induces the differentiation of acute myeloid leukemia cells and weakens their stemness potential <ref type="bibr" target="#b78">(83)</ref>.</p><p>Activated lipid metabolism has been found to promote cancer development both in vitro and in vivo <ref type="bibr" target="#b11">(11,</ref><ref type="bibr" target="#b79">84)</ref>. Treatment with exogenous palmitate enhances Src-dependent mitochondrial b-oxidation, increases the level of Src kinase localized in the cell membrane, and activates Src-mediated downstream MAPK and FAK signaling <ref type="bibr" target="#b74">(78)</ref>. These results reveal that dietary palmitate, in collaboration with elevated Src kinase, accelerates prostate tumor progression <ref type="bibr" target="#b74">(78)</ref>. CD36, a fatty acid transporter, is widely expressed in immune cells and tumor cells <ref type="bibr" target="#b80">(85)</ref>. CD36 can be palmitoylated by zDHHC4 and zDHHC5 at both N-terminal and C-terminal cysteine residues <ref type="bibr" target="#b81">(86)</ref>. zDHHC4 and zDHHC5 function at different subcellular localizations and regulate CD36 S-palmitoylation, targeting it to the plasma membrane for fatty acid uptake <ref type="bibr" target="#b82">(87)</ref>. Inhibiting CD36 S-palmitoylation reduces the hydrophobicity of the CD36 protein and its localization in the plasma membrane of hepatocytes. Depletion of either zDHHC4 or zDHHC5 disrupts the capability of adipose tissues to uptake fatty acids <ref type="bibr" target="#b83">(88)</ref>. These findings demonstrate the critical role of zDHHC4 and zDHHC5 in regulating CD36 S-palmitoylation and fatty acid uptake.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4">Proteins S-palmitoylation in antitumor immunity</head><p>Numerous palmitoylated proteins play a crucial role in IFN-g, Nucleotide oligomerization domain (NOD)-like receptors 1 and 2 (NOD1/2), Stimulator of interferon genes (STING), and JAK-STAT signaling pathways, which are closely associated with anti-tumor immunity <ref type="bibr" target="#b2">(3,</ref><ref type="bibr" target="#b84">89)</ref>. Recent studies have also started investigating the impact of protein S-palmitoylation on the regulation of the tumor immune microenvironment, particularly in relation to IFN-g and PD-1/PD-L1 signaling (Figure <ref type="figure">3</ref>) <ref type="bibr" target="#b32">(33)</ref>. Understanding the influence o f p r o t e in S -p a l m i t oy l a t i o n on t h e t u m o r i m m u n e microenvironment is a significant driving force behind current research in this field.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.1">S-palmitoylation regulates innate immunity</head><p>IFN-g is a cytokine secreted by various activated immune cells, including NK and CD8 + T cells <ref type="bibr" target="#b85">(90)</ref>. Binding of IFNg to its receptor activates the JAK-STAT pathway, inducing the expression of classical interferon-stimulated genes that play a critical role in antitumor responses <ref type="bibr" target="#b85">(90)</ref>. Recent research has discovered that Spalmitoylation of IFN-g receptor 1 (IFNGR1) at cysteine 122 acts as a sorting signal for IFNGR1 lysosomal degradation, mediated by AP3D1 in CRC <ref type="bibr" target="#b86">(91,</ref><ref type="bibr" target="#b87">92)</ref>. OPTN, which is lost in early-stage human CRC, interacts with AP3D1 to hinder its recognition of IFNGR1, thereby maintaining IFNGR1 stability and the integrity of downstream MHC-I signaling. This promotes antigen presentation to T cells and inhibits CRC progression <ref type="bibr" target="#b87">(92)</ref>.</p><p>NOD1/2 are intracellular pattern-recognition proteins that recognize peptidoglycan associated with microorganisms. The activation of NOD signaling is crucial for host defense against infections <ref type="bibr" target="#b88">(93)</ref>. Studies have demonstrated that zDHHC5 palmitoylates NOD1/2, which is necessary for its membrane localization and induction of NF-kB signaling in response to peptidoglycan <ref type="bibr" target="#b89">(94)</ref>. Toll-like receptor 4 (TLR4) is a pattern recognition receptor expressed by various innate immune cells, including macrophages, dendritic cells, and neutrophils <ref type="bibr" target="#b90">(95)</ref>. TLR4 participates in inflammasome activation by triggering downstream myeloid differentiation primary response protein (MYD88) signaling, leading to the release of inflammatory factors TNF-a, IL-1b, and IL-18 <ref type="bibr" target="#b91">(96)</ref>. The binding of IRAK4 to the MYD88 intermediate domain and subsequent signal activation require MYD88 S-palmitoylation at cysteine 113 <ref type="bibr" target="#b92">(97)</ref>. The S-palmitoylation of MYD88 is facilitated by de novo fatty acid synthesis and CD36-mediated incorporation of exogenous fatty acids. zDHHC6 is responsible for palmitoylating MYD88, and knockdown of zDHHC6 reduces MYD88 Spalmitoylation and impairs TLR/MYD88 activation upon lipopolysaccharide stimulus in neutrophils <ref type="bibr" target="#b92">(97)</ref>.</p><p>STING plays a crucial role in the innate immune response during infection <ref type="bibr" target="#b93">(98)</ref>. Research has shown that STING expression is elevated in patients with RCC and controls tumor growth through non-standard innate immune signaling involving the maintenance of mitochondrial ROS and calcium homeostasis <ref type="bibr" target="#b94">(99)</ref>. STING interacts with mitochondrial voltage-dependent anion channel (VDAC2) via STING-C88/C91 palmitoylation. zDHHC3, zDHHC7, and zDHHC15 palmitoylate STING in the Golgi apparatus of C89/91 <ref type="bibr" target="#b94">(99)</ref>. Depletion of STING enhances the formation of mitochondria-ER contacts mediated by VDAC2/ grp75, leading to increased levels of mitochondrial ROS/calcium and damage to mitochondrial function. Recently, covalently bound small molecule inhibitors that target STING palmitoylation have been developed, further confirming the critical role of STING palmitoylation in its assembly into polymeric complexes in the Golgi apparatus and the activation of downstream STING-triggered inflammatory signals <ref type="bibr" target="#b95">(100)</ref>. These studies reveal the significance of S-palmitoylation of STING in regulating mitochondrial function and growth in RCC, providing a rationale for targeting STING palmitoylation in the treatment of RCC.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>A B C</head><note type="other">FIGURE 3</note><p>The functional roles of protein S-palmitoylation in anti-tumor immunity. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.2">S-palmitoylation regulates acquired immunity</head><p>T cells play a crucial role in the adaptive immune response. Recent evaluation of the palmitome in primary T cells and Jurkat T cells revealed a pool of 120 palmitoylated proteins <ref type="bibr" target="#b96">(101)</ref>. This pool includes both well-known palmitoylated proteins and 92 previously unidentified palmitoylated proteins in vivo. Among the known palmitoylated proteins are ERBB2IP, FASN, CD44, and products of 52 genes associated with breast cancer metastasis to bone, lung, or brain <ref type="bibr" target="#b97">(102)</ref>. The study also demonstrated that certain PAT enzymes are themselves palmitoylated, suggesting the presence of a feedback mechanism. Furthermore, differential S-palmitoylation of T-cell surface antigens (mono-versus dual-lipidation) was observed, which likely contributes to increased functional flexibility. Previous studies have shown that S-palmitoylation regulates various components of the T-cell receptor (TCR) signaling pathway <ref type="bibr" target="#b57">(59)</ref>. S-palmitoylation has also been found to impact the T-cell co-receptors CD4 and CD8, as well as associated signaling molecules such as SRC family kinases LCK and FYN <ref type="bibr" target="#b98">(103)</ref>. Specifically, S-palmitoylation of CD4 on cysteine residues Cys396 and Cys399 near the membrane is associated with LCK, and together they enhance the enrichment and localization of CD4 in lipid rafts <ref type="bibr" target="#b2">(3)</ref>. Similarly, S-palmitoylation of CD8b is essential for the effective functioning of the CD8 co-receptor, as it increases the association of CD8 with p56lck and enhances p56lck activation in lipid rafts <ref type="bibr" target="#b99">(104)</ref>. In addition to N-terminal glycine myristoylation, LCK is palmitoylated on Cys3 and Cys5 <ref type="bibr" target="#b100">(105)</ref>. Both zDHHC2 and zDHHC21 have been identified as enzymes responsible for palmitoylating LCK <ref type="bibr" target="#b84">(89,</ref><ref type="bibr" target="#b101">106)</ref>. S-palmitoylation plays a critical role in the plasma membrane targeting of LCK and the phosphorylation of its substrates, such as CD8. Knockdown of zDHHC21 leads to decreased LCK S-palmitoylation and subsequently reduced T-cell activation.</p><p>Calcium signaling plays a crucial role in T cell signaling, with calcium increases primarily mediated by 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 (PLC-g1). PLC-g1 activates the production of inositol triphosphate, which then binds to the inositol triphosphate receptor, triggering an increase in calcium levels within the cell membrane <ref type="bibr" target="#b102">(107)</ref>. zDHHC21 palmitoylates PLC-g1, and its activity is dynamically regulated by TCR signaling <ref type="bibr" target="#b57">(59)</ref>. Furthermore, the T cell activation adapter LAT undergoes S-palmitoylation at Cys26 and Cys29. This S-palmitoylation helps LAT efficiently distribute to membrane microdomains and enables its tyrosine phosphorylation. The plasma membrane targeting function of S-palmitoylation is crucial in TCR signaling, and the absence of LAT S-palmitoylation results in T cell inactivity <ref type="bibr" target="#b103">(108)</ref>.</p><p>JAK2/STAT3 is a crucial signaling pathway that plays a significant role in promoting inflammation and tumor progression <ref type="bibr" target="#b104">(109)</ref>. The activation of JAK2 occurs when extracellular IL-6 binds to its receptor on the cell membrane, subsequently leading to the activation of STAT3 signaling. Once phosphorylated, STAT3 translocates to the nucleus and functions as a transcription factor, facilitating the expression of downstream genes. In this context, zDHHC7 plays a noteworthy role by palmitoylating STAT3 at cysteine 108, which enhances its membrane recruitment and phosphorylation <ref type="bibr" target="#b105">(110)</ref>. Interestingly, phosphorylated STAT3 is depalmitoylated by APT2, allowing it to translocate to the nucleus. This palmitoylation-depalmitoylation cycle augments STAT3 activation, thereby promoting Th17 cell differentiation <ref type="bibr" target="#b105">(110)</ref>. The excessive activation of TH17 cells has been linked to various inflammatory diseases, including inflammatory bowel disease (IBD). In a mouse model, the inhibition of APT2 through pharmacological means or the knockout of zDHHC7 has been found to alleviate the symptoms associated with IBD <ref type="bibr" target="#b105">(110)</ref>. These findings not only propose a potential therapeutic strategy for treating IBD but also provide insights into the role of S-palmitoylation in regulating cell signaling, which could have broader implications for understanding the functional significance of various S-palmitoylation events.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="4.3">S-palmitoylation regulates immune checkpoints</head><p>Immune checkpoint inhibitors have been widely utilized in tumor immunotherapy. PD-L1, a transmembrane protein, is highly expressed on various types of cancer cells. By binding to its receptor PD-1 on T cells, PD-L1 significantly inhibits T cell activation and activity, thereby playing a crucial role in enabling tumor cells to evade immune surveillance <ref type="bibr" target="#b106">(111)</ref>. Antibodies that block PD-L1/PD-1 interactions have revolutionized cancer treatment, showing promising clinical outcomes in melanoma, lung, bladder, colorectal, and renal cell carcinoma. However, the response rate to PD-L1/PD-1 antibody therapy is less satisfactory in other cancers such as prostate, ovarian, and breast cancer. In breast cancer, PD-L1 has been found to be palmitoylated by zDHHC9 at the C272 site, enhancing its stability <ref type="bibr" target="#b32">(33)</ref>. Mutation of Cys272 to Ala dramatically abolishes mPD-L1 palmitoylation, or inhibiting the expression of zDHHC9 sensitizes breast cancer cells to T-cell killing, thereby repressing tumor growth <ref type="bibr" target="#b32">(33)</ref>. Another study discovered that S-palmitoylation of PD-L1 at Cys272 inhibits its ubiquitinationmediated lysosomal degradation. zDHHC3 is the primary acyltransferase responsible for PD-L1 S-palmitoylation, and inhibiting PD-L1 S-palmitoylation using 2-BP or silencing DHHC3 activates anti-tumor immunity in CRC <ref type="bibr" target="#b107">(112)</ref>. The same group further elucidated the regulatory role of S-palmitoylation in PD-1 stability in tumor cells. Mechanistically, zDHHC9 mediates PD-1 palmitoylation at C192, promoting its binding with recycling endosomes and preventing lysosome-dependent degradation <ref type="bibr" target="#b108">(113)</ref>. They demonstrated that palmitoylation of PD-1, but not PD-L1, promotes mTOR signaling and tumor cell proliferation.</p><p>S-palmitoylation of PD-L1 plays a crucial role in regulating its stability. It inhibits the monoubiquitination of PD-L1, thereby preventing its passage through the endosomal sorting complex required for transport (ESCRT). Consequently, the degradation of PD-L1 via the lysosomal pathway is blocked, leading to increased expression of PD-L1 on the cell surface. This increased expression of PD-L1 inhibits the cytotoxicity of T cells. In order to enhance the lethality of cytotoxic T cells against cancer cells, researchers developed a competitive peptide that specifically inhibits PD-L1, surpassing the commonly used universal palmitoylation inhibitor 2-BP in terms of specificity. As a result, the inhibitor reduced the expression of PD-L1 in tumor cells. These findings highlight the significant antitumor effects of targeted S-palmitoylation in vitro and offer promising opportunities for the development of new approaches in cancer immunotherapy.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="5">Targeting protein S-palmitoylation for cancer treatment</head><p>Protein S-palmitoylation plays a crucial role in cancer progression and anti-tumor immunity, making it an attractive target for cancer therapy. Inhibitors of palmitoylation could be beneficial for anticancer treatment, as many oncogenes require S-palmitoylation modification for proper localization on the cellular membrane. Currently, there are no potent and specific inhibitors for zDHHC enzymes. While broad-spectrum protein Spalmitoylation inhibitors like 2-BP are commonly used to validate anticancer effects and have been employed in pre-clinical studies <ref type="bibr" target="#b38">(39)</ref>, they lack selectivity for individual zDHHC enzymes and can acylate other intracellular proteins, making them unsuitable as drug leads or therapeutic candidates <ref type="bibr" target="#b25">(25)</ref>. Through a FRET-based high throughput assay screening of over 350,000 compounds, two related tetrazole-containing compounds (TTZ-1 and TTZ-2) were identified that inhibit both zDHHC2 autopalmitoylation and substrate palmitoylation in cell-free systems <ref type="bibr" target="#b109">(114)</ref>. However, it remains to be investigated whether these compounds or their derivatives can inhibit other mammalian zDHHC enzymes in cancer or immune cells. Crystal structures of zDHHC20 and zDHHC15 have been reported <ref type="bibr" target="#b22">(22,</ref><ref type="bibr" target="#b109">114)</ref>, and structure-guided methods can be used to develop inhibitors that target specific zDHHC enzymes at their binding domains <ref type="bibr" target="#b22">(22)</ref>. However, obtaining structures of additional zDHHC enzymes would be necessary to discover inhibitors that are specific to one enzyme over another. Moreover, since many proteins can be palmitoylated by multiple zDHHC enzymes, specific inhibitors for individual zDHHC enzymes may not be clinically useful as they may target multiple zDHHC family members. A potential solution to this challenge would be to develop inhibitors that can block the function of several specific palmitoylation enzymes for a single target.</p><p>Palmitate-derived palmitoyl-CoA supports protein palmitoylation in cancer cells or immune cells. Previous studies have shown that inhibiting palmitate generation by FASN inhibitors such as TVB-3166 or TVB-3664 significantly reduces palmitate generation and tubulin S-palmitoylation <ref type="bibr" target="#b110">(115)</ref>. Combining FASN inhibition with taxane treatment enhances the inhibition of in vitro tumor cell growth in lung, ovarian, prostate, and pancreatic cancers. Competitive inhibition of substrate S-palmitoylation is an effective method for targeting specific zDHHC enzymes. It is conceivable that a small molecule or polypeptide could inhibit zDHHC-protein substrate interactions, which are necessary for substrate S-palmitoylation. This competitive inhibition strategy could be used to develop more specific palmitoylation inhibitors. In a previous study, a polypeptide containing the PD-L1 (265aa-279aa) sequence, which includes the S-palmitoylation site of PD-L1, was developed <ref type="bibr" target="#b107">(112)</ref>. The polypeptide sequence near the S-palmitoylation site may inhibit the S-palmitoylation of endogenous PD-L1 by competitively binding to zDHHC3. The results show that this polypeptide can effectively reduce the S-palmitoylation of PD-L1, thereby significantly decreasing the expression of PD-L1 in tumor cells. This study suggests that a competitive inhibition strategy can effectively inhibit the S-palmitoylation of PD-L1.</p><p>Rather than inhibiting protein S-palmitoylation, it may sometimes be more effective to focus on preventing depalmitoylation. Several small molecule inhibitors have been developed for this purpose, including the pan-depalmitoylation inhibitor PalmB, as well as the APT1-and APT2-specific inhibitors ML348 and ML349 <ref type="bibr">(116,</ref><ref type="bibr" target="#b111">117)</ref>. Inhibiting APT enzymes can suppress tumor formation by promoting the proper localization of SCRIB and enhancing the activity of melanocortin-1 receptor (MC1R) <ref type="bibr" target="#b112">(118)</ref><ref type="bibr" target="#b113">(119)</ref><ref type="bibr" target="#b114">(120)</ref>. In addition to regulating tumor suppressor function through inhibition of APT1/2, inhibiting lysosomal PPT1mediated depalmitoylation may have a more direct toxic effect on cancer cells <ref type="bibr" target="#b115">(121)</ref>. Cells lacking PPT1 exhibit abnormal accumulation of palmitoylated protein in the ER <ref type="bibr" target="#b116">(122)</ref>. This protein leads to activation of the unfolded protein response (UPR) pathway and increased expression of chaperone proteins such as glucose-regulatory protein-78. The abnormal accumulation of protein also mediates caspase-12 and caspase-3 activation, ultimately inducing apoptosis <ref type="bibr" target="#b117">(123)</ref>. Inhibition of PPT1 by the natural product didemnin B may inhibit lysosomal acidification and induce apoptosis. In this case, apoptosis is caused by the loss of the rapidly degraded pro-survival protein MCL1. Apart from disrupting lysosome function, DQ661 or didemnin B might also cause protein synthesis inhibition, lysosomal membrane permeabilization, and apoptosis via mTOR signaling <ref type="bibr" target="#b118">(124)</ref>. DQ661 inhibits the mTOR pathway by preventing RAGC, MTOR, and other key molecules from associating with the lysosomal surface. PPT1 inhibition by HCQ or DC661 induces cGAS/STING/TBK1 pathway activation and interferon-b release in macrophages, enhancing the antitumor efficacy of anti-PD-1 Ab in melanoma <ref type="bibr" target="#b119">(125)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head n="6">Concluding remarks</head><p>S-palmitoylation plays a role in various aspects of tumor cell proliferation, metastasis <ref type="bibr" target="#b120">(126)</ref>, and apoptosis, impacting tumors by influencing antitumor immunity in the tumor microenvironment <ref type="bibr" target="#b121">(127)</ref>. Abnormal expression of zDHHCs, APTs, and PPTs, as well as changes in the S-palmitoylation status of cancer-associated proteins, have been observed in almost all types of cancer. Previous studies have shown that inhibition of some members of the zDHHC family such as zDHHC3, 5, 17, 9, 12 inhibited tumor progression and enhanced the therapeutic efficacy of PD-1/PD-L1 checkpoint antibody blockade in CRC, glioblastoma, leukemia, and pancreatic cancer <ref type="bibr" target="#b32">(33,</ref><ref type="bibr">80,</ref><ref type="bibr" target="#b122">128,</ref><ref type="bibr" target="#b123">129)</ref>. These findings suggest that targeting either zDHHCs and PPTs or palmitoylated cancer-associated proteins could potentially benefit the treatment of different cancer types. However, it is important to note that inhibiting protein S-palmitoylation can have toxic effects on normal cells. Despite this caution, there is strong evidence supporting the targeting of PAT enzymes as a potential approach to treating cancer <ref type="bibr" target="#b12">(12,</ref><ref type="bibr" target="#b119">125)</ref>. For instance, oncoproteins like RAS-family GTPases rely on S-palmitoylation to promote tumor formation. Inhibiting the function of oncoproteins by blocking this key posttranslational modification is an appealing strategy, particularly for undruggable proteins such as RAS.</p><p>In recent years, there has been rapid development in tumor immunotherapy, which has shown promising results in some patients, offering the potential for long-lasting treatment. However, current cancer immunotherapy still faces challenges such as low response rates and the risk of serious immune-related adverse events. The effectiveness of tumor immunotherapy largely depends on the tumor microenvironment, particularly the tumor immune microenvironment. Therefore, understanding the regulatory mechanism of S-palmitoylation in the tumor microenvironment can serve as a theoretical foundation for intervening in Spalmitoylation to regulate the tumor immune microenvironment. This understanding can pave the way for improving the efficacy of immunotherapy by providing a new direction.</p><p>In summary, the investigation of the regulatory mechanism of protein S-palmitoylation, a post-translational modification, on the tumor immune microenvironment is a crucial and promising research area in the field of tumor immunity. Understanding this mechanism can have significant clinical implications and contribute to the advancement of tumor immunotherapy.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head></head><label></label><figDesc>(A) Palmitoylation regulates the IFNGR, NOD and TLR pathways. (B) Protein S-palmitoylation in T cell activation and immune regulation. (C) Protein S-palmitoylation regulates immune checkpoints.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="2,136.83,470.62,326.02,203.56" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0"><head></head><label></label><figDesc></figDesc><graphic coords="7,122.52,522.97,354.37,191.59" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>TABLE 1</head><label>1</label><figDesc>An overview of the function of zDHHCs in cancers.</figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell>ZDHHC1</cell><cell>ER, Golgi</cell><cell>zDHHC1 plays a crucial</cell><cell>P53,</cell></row><row><cell></cell><cell></cell><cell>role in p53 palmitoylation</cell><cell>IFITM3</cell></row><row><cell></cell><cell></cell><cell>at the C135, C176, and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>C275 residues, facilitating</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the nuclear translocation</cell><cell></cell></row><row><cell></cell><cell></cell><cell>of p53. Additionally, it has</cell><cell></cell></row><row><cell></cell><cell></cell><cell>a function in DNA virus-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>triggered and CGAS-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mediated innate immune</cell><cell></cell></row><row><cell></cell><cell></cell><cell>response, independent of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>its palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity. zDHHC1 acts as</cell><cell></cell></row><row><cell></cell><cell></cell><cell>an activator of STING1 by</cell><cell></cell></row><row><cell></cell><cell></cell><cell>promoting the cGAMP-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>induced oligomerization of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>STING1 and facilitating</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the recruitment of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>downstream</cell><cell></cell></row><row><cell></cell><cell></cell><cell>signaling components.</cell><cell></cell></row><row><cell>ZDHHC2</cell><cell>ER, Golgi</cell><cell>zDHHC2 functions as a</cell><cell>AGK, LCK,</cell></row><row><cell></cell><cell></cell><cell>mediator of AGK</cell><cell>CD9,</cell></row><row><cell></cell><cell></cell><cell>palmitoylation, facilitating</cell><cell>CD151</cell></row><row><cell></cell><cell></cell><cell>AGK translocation to the</cell><cell>CKAP4</cell></row><row><cell></cell><cell></cell><cell>plasma membrane and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activating the PI3K-AKT-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mTOR signaling pathway</cell><cell></cell></row><row><cell></cell><cell></cell><cell>in RCC. It also plays a</cell><cell></cell></row><row><cell></cell><cell></cell><cell>crucial role in cell</cell><cell></cell></row><row><cell></cell><cell></cell><cell>adhesion by</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylating CD9 and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>CD151, thereby regulating</cell><cell></cell></row><row><cell></cell><cell></cell><cell>their expression and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>function. Furthermore,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>zDHHC2 palmitoylates</cell><cell></cell></row><row><cell></cell><cell></cell><cell>CKAP4, which in turn</cell><cell></cell></row><row><cell></cell><cell></cell><cell>influences its localization</cell><cell></cell></row><row><cell></cell><cell></cell><cell>to the plasma membrane.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, zDHHC2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>has the potential to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylate LCK and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulate its localization to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the plasma membrane.</cell><cell></cell></row><row><cell>ZDHHC3</cell><cell>Golgi</cell><cell>zDHHC3 is responsible</cell><cell>PPT1,</cell></row><row><cell></cell><cell></cell><cell>for palmitoylating PPT1,</cell><cell>APT2,</cell></row><row><cell></cell><cell></cell><cell>leading to a reduction in</cell><cell>ITGb4, PD-</cell></row><row><cell></cell><cell></cell><cell>PPT1 enzyme activity. It</cell><cell>L1, STING</cell></row><row><cell></cell><cell></cell><cell>also plays a role in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mediating APT2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation at Cys2,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>which allows APT2 to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>stably bind to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>membrane and search for</cell><cell></cell></row><row><cell></cell><cell></cell><cell>potential substrates.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, zDHHC3</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates ITGA6 and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ITGB4, thereby regulating</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the localization,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>expression, and function</cell><cell></cell></row><row><cell></cell><cell></cell><cell>of the alpha-6/beta-4</cell><cell></cell></row><row><cell></cell><cell></cell><cell>integrin in cell adhesion to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>laminin. Moreover, the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation of PD-L1</cell><cell></cell></row><row><cell></cell><cell></cell><cell>at Cys272 inhibits its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ubiquitination-mediated</cell><cell></cell></row><row><cell></cell><cell></cell><cell>lysosomal degradation.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Lastly, zDHHC3 is</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>TABLE 1 Continued</head><label>1</label><figDesc></figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell></cell><cell></cell><cell>involved in palmitoylating</cell><cell></cell></row><row><cell></cell><cell></cell><cell>STING in the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Golgi apparatus.</cell><cell></cell></row><row><cell>ZDHHC4</cell><cell>ER, Golgi,</cell><cell>zDHHC4 is involved in</cell><cell>GSK3b</cell></row><row><cell></cell><cell>Plasma</cell><cell>mediating the</cell><cell></cell></row><row><cell></cell><cell>membrane</cell><cell>palmitoylation of GSK3b,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>which contributes to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>promotion of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>tumorigenicity in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>temozolomide-resistant</cell><cell></cell></row><row><cell></cell><cell></cell><cell>glioblastoma stem cells.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>This effect is achieved</cell><cell></cell></row><row><cell></cell><cell></cell><cell>through the EZH2-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>STAT3 axis.</cell><cell></cell></row><row><cell>ZDHHC5</cell><cell>Plasma</cell><cell>zDHHC5 participates in</cell><cell>CTNND2,</cell></row><row><cell></cell><cell>membrane</cell><cell>the uptake of fatty acids</cell><cell>CD36,</cell></row><row><cell></cell><cell></cell><cell>by palmitoylating CD36,</cell><cell>NOD1,</cell></row><row><cell></cell><cell></cell><cell>facilitating its</cell><cell>NOD2,</cell></row><row><cell></cell><cell></cell><cell>transportation to the</cell><cell>STAT3</cell></row><row><cell></cell><cell></cell><cell>plasma membrane.</cell><cell>and S1PR1</cell></row><row><cell></cell><cell></cell><cell>zDHHC5 is responsible</cell><cell></cell></row><row><cell></cell><cell></cell><cell>for the palmitoylation of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>NOD1/2, enabling its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>membrane and subsequent</cell><cell></cell></row><row><cell></cell><cell></cell><cell>induction of NF-kB</cell><cell></cell></row><row><cell></cell><cell></cell><cell>signaling in response to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>peptidoglycan.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Furthermore, ZDHHC5</cell><cell></cell></row><row><cell></cell><cell></cell><cell>plays a crucial role in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating oligodendrocyte</cell><cell></cell></row><row><cell></cell><cell></cell><cell>development by catalyzing</cell><cell></cell></row><row><cell></cell><cell></cell><cell>STAT3 palmitoylation.</cell><cell></cell></row><row><cell>ZDHHC6</cell><cell>ER</cell><cell>zDHHC6 is responsible</cell><cell>AEG-1,</cell></row><row><cell></cell><cell></cell><cell>for palmitoylating ITPR1</cell><cell>AMFR,</cell></row><row><cell></cell><cell></cell><cell>in immune cells, which</cell><cell>calnexin,</cell></row><row><cell></cell><cell></cell><cell>helps regulate the stability</cell><cell>ITPR1</cell></row><row><cell></cell><cell></cell><cell>and function of ITPR1.</cell><cell>and TFRC</cell></row><row><cell></cell><cell></cell><cell>Additionally, zDHHC6</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates MYD88, and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>when zDHHC6 is knocked</cell><cell></cell></row><row><cell></cell><cell></cell><cell>down, it reduces MYD88</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation and TLR/</cell><cell></cell></row><row><cell></cell><cell></cell><cell>MYD88 activation.</cell><cell></cell></row><row><cell>ZDHHC7</cell><cell>Golgi</cell><cell>zDHHC7 palmitoylates</cell><cell>STAT3</cell></row><row><cell></cell><cell></cell><cell>STAT3 at cysteine 108,</cell><cell>FAS,</cell></row><row><cell></cell><cell></cell><cell>facilitating its recruitment</cell><cell>SCRIB,</cell></row><row><cell></cell><cell></cell><cell>and phosphorylation at</cell><cell>ESR1, PGR</cell></row><row><cell></cell><cell></cell><cell>the cell membrane.</cell><cell>and</cell></row><row><cell></cell><cell></cell><cell>Moreover, it plays a role</cell><cell>AR, GNAQ</cell></row><row><cell></cell><cell></cell><cell>in regulating the FAS</cell><cell></cell></row><row><cell></cell><cell></cell><cell>signaling pathway by</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylating and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>stabilizing the receptor at</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the plasma membrane.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>zDHHC6 also</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates SCRIB,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>controlling its localization</cell><cell></cell></row><row><cell></cell><cell></cell><cell>to the plasma membrane,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>which indirectly affects cell</cell><cell></cell></row><row><cell></cell><cell></cell><cell>polarity and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>differentiation.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Furthermore, it</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates JAM3,</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>TABLE 1 Continued</head><label>1</label><figDesc></figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell></cell><cell></cell><cell>enhancing its expression</cell><cell></cell></row><row><cell></cell><cell></cell><cell>at tight junctions and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating its function in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cell migration.</cell><cell></cell></row><row><cell>ZDHHC8</cell><cell>Golgi</cell><cell>zDHHC8 is responsible</cell><cell>ABCA1,</cell></row><row><cell></cell><cell></cell><cell>for palmitoylating ABCA1,</cell><cell>DRD2</cell></row><row><cell></cell><cell></cell><cell>which plays a crucial role</cell><cell></cell></row><row><cell></cell><cell></cell><cell>in regulating the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization of the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>transporter to the plasma</cell><cell></cell></row><row><cell></cell><cell></cell><cell>membrane. This, in turn,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>affects the function of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ABCA1 in cholesterol and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>phospholipid efflux.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, zDHHC8</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates the D2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>dopamine receptor DRD2,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>thereby regulating its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>stability and localization</cell><cell></cell></row><row><cell></cell><cell></cell><cell>to the plasma membrane.</cell><cell></cell></row><row><cell>ZDHHC9/</cell><cell>ER, Golgi</cell><cell>zDHHC9/10 plays a</cell><cell>GLUT1,</cell></row><row><cell>ZDHHC10</cell><cell></cell><cell>crucial role in the</cell><cell>HRAS,</cell></row><row><cell></cell><cell></cell><cell>palmitoylation of GLUT1</cell><cell>ADRB2</cell></row><row><cell></cell><cell></cell><cell>at C207, which enhances</cell><cell></cell></row><row><cell></cell><cell></cell><cell>its localization to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>plasma membrane and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>promotes a high level of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>glycolysis in glioblastoma.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>The zDHHC9-GOLGA7</cell><cell></cell></row><row><cell></cell><cell></cell><cell>complex serves as a</cell><cell></cell></row><row><cell></cell><cell></cell><cell>specific</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase for</cell><cell></cell></row><row><cell></cell><cell></cell><cell>HRAS and NRAS.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, it may</cell><cell></cell></row><row><cell></cell><cell></cell><cell>exhibit</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity towards the beta-2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>adrenergic receptor/</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ADRB2, thereby</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating G protein-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>coupled receptor signaling.</cell><cell></cell></row><row><cell>ZDHHC11</cell><cell>ER</cell><cell>zDHHC11 exhibits</cell><cell>NCDN</cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity towards NCDN</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and plays a role in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating cell</cell><cell></cell></row><row><cell></cell><cell></cell><cell>proliferation. It also has a</cell><cell></cell></row><row><cell></cell><cell></cell><cell>function independent of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>its palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity, specifically in the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DNA virus-triggered and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>CGAS-mediated innate</cell><cell></cell></row><row><cell></cell><cell></cell><cell>immune response.</cell><cell></cell></row><row><cell>ZDHHC11B</cell><cell>Membrane, Golgi</cell><cell>May play a role in</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>cell proliferation.</cell><cell></cell></row><row><cell>ZDHHC12</cell><cell>ER, Golgi</cell><cell>zDHHC12 is responsible</cell><cell>CLDN3,</cell></row><row><cell></cell><cell></cell><cell>for mediating S-</cell><cell>GPHN,</cell></row><row><cell></cell><cell></cell><cell>palmitoylation of CLDN3</cell><cell>NLRP3</cell></row><row><cell></cell><cell></cell><cell>at amino acid positions</cell><cell></cell></row><row><cell></cell><cell></cell><cell>C181, C182, and C184.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>This modification</cell><cell></cell></row><row><cell></cell><cell></cell><cell>contributes to the accurate</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>stabilization of CLDN3 on</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>TABLE 1 Continued</head><label>1</label><figDesc></figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell></cell><cell></cell><cell>the plasma membrane,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>particularly in ovarian</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cancer. Additionally,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>zDHHC12 acts as an</cell><cell></cell></row><row><cell></cell><cell></cell><cell>inhibitor of the NLRP3</cell><cell></cell></row><row><cell></cell><cell></cell><cell>inflammasome by</cell><cell></cell></row><row><cell></cell><cell></cell><cell>facilitating the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation of NLRP3,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ultimately promoting</cell><cell></cell></row><row><cell></cell><cell></cell><cell>its degradation.</cell><cell></cell></row><row><cell>ZDHHC13</cell><cell>ER, Golgi</cell><cell>zDHHC13-dependent</cell><cell>Drp1, HTT</cell></row><row><cell></cell><cell></cell><cell>Drp1 palmitoylation</cell><cell>MC1R,</cell></row><row><cell></cell><cell></cell><cell>results in the normal</cell><cell>GAD2</cell></row><row><cell></cell><cell></cell><cell>occurrence of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mitochondria fission-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>fusion processes. It acts as</cell><cell></cell></row><row><cell></cell><cell></cell><cell>a palmitoyltransferase for</cell><cell></cell></row><row><cell></cell><cell></cell><cell>HTT and GAD2.</cell><cell></cell></row><row><cell>ZDHHC14</cell><cell>ER, Golgi</cell><cell>zDHHC14 inhibits acute</cell><cell>ADRB2</cell></row><row><cell></cell><cell></cell><cell>myeloid leukemia cellular</cell><cell></cell></row><row><cell></cell><cell></cell><cell>differentiation. It also</cell><cell></cell></row><row><cell></cell><cell></cell><cell>exhibits</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity towards the beta-2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>adrenergic receptor/</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ADRB2, thereby</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating G protein-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>coupled receptor signaling.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, it may play a</cell><cell></cell></row><row><cell></cell><cell></cell><cell>role in cell differentiation</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and apoptosis.</cell><cell></cell></row><row><cell>ZDHHC15</cell><cell>Golgi</cell><cell>zDHHC15 palmitoylates</cell><cell>IGF2R,</cell></row><row><cell></cell><cell></cell><cell>IGF2R and SORT1,</cell><cell>SORT1,</cell></row><row><cell></cell><cell></cell><cell>facilitating their</cell><cell>GAP43</cell></row><row><cell></cell><cell></cell><cell>localization to a specific</cell><cell></cell></row><row><cell></cell><cell></cell><cell>subdomain of the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>endosomal membrane.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>This localization enables</cell><cell></cell></row><row><cell></cell><cell></cell><cell>their interaction with the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>retromer cargo-selective</cell><cell></cell></row><row><cell></cell><cell></cell><cell>complex. zDHHC15 also</cell><cell></cell></row><row><cell></cell><cell></cell><cell>mediates STING</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation in the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Golgi apparatus and has</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the potential to catalyze</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the palmitoylation</cell><cell></cell></row><row><cell></cell><cell></cell><cell>of GAP43.</cell><cell></cell></row><row><cell>ZDHHC16</cell><cell>ER</cell><cell>zDHHC16 is responsible</cell><cell>ZDHHC6,</cell></row><row><cell></cell><cell></cell><cell>for palmitoylating</cell><cell>PCSK9</cell></row><row><cell></cell><cell></cell><cell>ZDHHC6, which affects</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the quaternary assembly,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization, stability, and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>function of ZDHHC6.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation of PCSK9</cell><cell></cell></row><row><cell></cell><cell></cell><cell>at cysteine 600 enhances</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the binding affinity</cell><cell></cell></row><row><cell></cell><cell></cell><cell>between PCSK9</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and PTEN.</cell><cell></cell></row><row><cell>ZDHHC17</cell><cell>Golgi</cell><cell>zDHHC17 palmitoylates</cell><cell>CASP6,</cell></row><row><cell></cell><cell></cell><cell>Caspse6, preventing its</cell><cell>SNAP25</cell></row><row><cell></cell><cell></cell><cell>dimerization and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>subsequent activation.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Moreover, zDHHC17 may</cell><cell></cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_4"><head>TABLE 1 Continued</head><label>1</label><figDesc></figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell></cell><cell></cell><cell>play a role in the sorting</cell><cell></cell></row><row><cell></cell><cell></cell><cell>or targeting of crucial</cell><cell></cell></row><row><cell></cell><cell></cell><cell>proteins involved in the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>initial stages of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>endocytosis at the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>plasma membrane.</cell><cell></cell></row><row><cell>ZDHHC18</cell><cell>Golgi</cell><cell>Palmitoylation of MDH2,</cell><cell>MDH2,</cell></row><row><cell></cell><cell></cell><cell>catalyzed by zDHHC18 at</cell><cell>CGAS,</cell></row><row><cell></cell><cell></cell><cell>C138, results in the</cell><cell>HRAS,</cell></row><row><cell></cell><cell></cell><cell>activation of</cell><cell>LCK,</cell></row><row><cell></cell><cell></cell><cell>mitochondrial respiration</cell><cell>ADRB2</cell></row><row><cell></cell><cell></cell><cell>and promotes the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>malignancy of ovarian</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cancer. Additionally, it</cell><cell></cell></row><row><cell></cell><cell></cell><cell>acts as a negative regulator</cell><cell></cell></row><row><cell></cell><cell></cell><cell>of the cGAS-STING</cell><cell></cell></row><row><cell></cell><cell></cell><cell>pathway by mediating the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>inactivation of CGAS.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>zDHHC18 may also</cell><cell></cell></row><row><cell></cell><cell></cell><cell>exhibit</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity towards the beta-2</cell><cell></cell></row><row><cell></cell><cell></cell><cell>adrenergic receptor/</cell><cell></cell></row><row><cell></cell><cell></cell><cell>ADRB2, thereby</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulating G protein-</cell><cell></cell></row><row><cell></cell><cell></cell><cell>coupled receptor signaling.</cell><cell></cell></row><row><cell>ZDHHC19</cell><cell>Cytoplasm, Golgi</cell><cell>Palmitoylation of SMAD3</cell><cell>SMAD3,</cell></row><row><cell></cell><cell></cell><cell>by zDHHC19 promotes</cell><cell>RRAS</cell></row><row><cell></cell><cell></cell><cell>the activation of the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>transforming growth</cell><cell></cell></row><row><cell></cell><cell></cell><cell>factor-beta (TGF-b)</cell><cell></cell></row><row><cell></cell><cell></cell><cell>signaling pathway.</cell><cell></cell></row><row><cell>ZDHHC20</cell><cell>Cytoplasm,</cell><cell>zDHHC20 palmitoylates</cell><cell>EGFR,</cell></row><row><cell></cell><cell>Golgi, ER</cell><cell>EGFR, leading to the</cell><cell>IFITM3</cell></row><row><cell></cell><cell></cell><cell>activation of EGFR</cell><cell></cell></row><row><cell></cell><cell></cell><cell>signaling. This, in turn,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>enhances cell migration</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and anchor-independent</cell><cell></cell></row><row><cell></cell><cell></cell><cell>growth in lung cancer.</cell><cell></cell></row><row><cell>ZDHHC21</cell><cell>Golgi, Plasma</cell><cell>zDHHC21 exhibits</cell><cell>AK2, EGFR,</cell></row><row><cell></cell><cell>membrane</cell><cell>specific catalytic activity in</cell><cell>eNOS, LCK,</cell></row><row><cell></cell><cell></cell><cell>the palmitoylation of AK2,</cell><cell>AR, FYN,</cell></row><row><cell></cell><cell></cell><cell>resulting in the activation</cell><cell>ADRA1DP,</cell></row><row><cell></cell><cell></cell><cell>of OXPHOS in leukemic</cell><cell>PLCB1</cell></row><row><cell></cell><cell></cell><cell>blasts. Additionally, it</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates FYN,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>thereby regulating its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization in hair follicles</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and playing a crucial role</cell><cell></cell></row><row><cell></cell><cell></cell><cell>in epidermal homeostasis</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and hair follicle</cell><cell></cell></row><row><cell></cell><cell></cell><cell>differentiation. The</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylation of PLCB1</cell><cell></cell></row><row><cell></cell><cell></cell><cell>and the subsequent</cell><cell></cell></row><row><cell></cell><cell></cell><cell>regulation of its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>downstream signaling</cell><cell></cell></row><row><cell></cell><cell></cell><cell>pathways may indirectly</cell><cell></cell></row><row><cell></cell><cell></cell><cell>influence the function of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the endothelial barrier and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the adhesion of leukocytes</cell><cell></cell></row><row><cell></cell><cell></cell><cell>to the endothelium.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Furthermore, ZDHHC21</cell><cell></cell></row><row><cell></cell><cell></cell><cell>demonstrates</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoyltransferase</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell>(Continued)</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_5"><head>TABLE 1 Continued</head><label>1</label><figDesc></figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell></cell><cell></cell><cell>activity towards ADRA1D,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>positively modulating its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>activity and expression,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>potentially contributing to</cell><cell></cell></row><row><cell></cell><cell></cell><cell>vascular contraction. It</cell><cell></cell></row><row><cell></cell><cell></cell><cell>may also be involved in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>the palmitoylation of</cell><cell></cell></row><row><cell></cell><cell></cell><cell>eNOS and LCK.</cell><cell></cell></row><row><cell>ZDHHC22</cell><cell>ER, Golgi</cell><cell>zDHHC22 palmitoylates</cell><cell>mTOR,</cell></row><row><cell></cell><cell></cell><cell>mTOR, leading to reduced</cell><cell>KCNMA1,</cell></row><row><cell></cell><cell></cell><cell>mTOR stability and</cell><cell>CNN3</cell></row><row><cell></cell><cell></cell><cell>decreased activation of the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>AKT signaling pathway.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>Additionally, zDHHC22</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitoylates KCNMA1,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>thereby regulating its</cell><cell></cell></row><row><cell></cell><cell></cell><cell>localization to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>plasma membrane.</cell><cell></cell></row><row><cell>ZDHHC23</cell><cell>Golgi</cell><cell>zDHHC23 palmitoylates</cell><cell>KCNMA1</cell></row><row><cell></cell><cell></cell><cell>KCNMA1, playing a role</cell><cell></cell></row><row><cell></cell><cell></cell><cell>in its localization to the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>plasma membrane.</cell><cell></cell></row><row><cell>ZDHHC24</cell><cell>Membrane</cell><cell>-</cell><cell>-</cell></row></table></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_6"><head>TABLE 2</head><label>2</label><figDesc>The function of depalmitoylation enzymes in cancers.</figDesc><table><row><cell>Gene</cell><cell cols="2">Localization Function</cell><cell>Target</cell></row><row><cell>APT1</cell><cell>Membrane,</cell><cell>APT1 and APT2 are</cell><cell>HRAS</cell></row><row><cell></cell><cell>Cytoplasm,</cell><cell>enzymes involved in the</cell><cell>NRAS,</cell></row><row><cell></cell><cell>ER, Nucleus</cell><cell>hydrolysis of fatty acids from</cell><cell>KCNMA1,</cell></row><row><cell></cell><cell></cell><cell>S-acylated cysteine residues</cell><cell>ADRB2,</cell></row><row><cell></cell><cell></cell><cell>in proteins. APT1 specifically</cell><cell>CKAP4,</cell></row><row><cell></cell><cell></cell><cell>acts on proteins such as</cell><cell>LPR6</cell></row><row><cell></cell><cell></cell><cell>trimeric G alpha proteins,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>HRAS, and ADRB2,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>displaying</cell><cell></cell></row><row><cell></cell><cell></cell><cell>depalmitoylating activity.</cell><cell></cell></row><row><cell>APT2</cell><cell>Cytoplasm</cell><cell>APT2 depalmitoylates</cell><cell>STAT3,</cell></row><row><cell></cell><cell></cell><cell>phosphorylated STAT3,</cell><cell>GAP43,</cell></row><row><cell></cell><cell></cell><cell>facilitating its translocation</cell><cell>ZDHHC6,</cell></row><row><cell></cell><cell></cell><cell>to the nucleus. Additionally,</cell><cell>HRAS</cell></row><row><cell></cell><cell></cell><cell>APT2 also hydrolyzes fatty</cell><cell></cell></row><row><cell></cell><cell></cell><cell>acids from S-acylated</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cysteine residues in proteins</cell><cell></cell></row><row><cell></cell><cell></cell><cell>like GAP43, ZDHHC6, and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>trimeric G alpha proteins.</cell><cell></cell></row><row><cell>PPT1</cell><cell>Lysosome,</cell><cell>PPT1 is responsible for</cell><cell>-</cell></row><row><cell></cell><cell>Secreted</cell><cell>removing thioester-linked</cell><cell></cell></row><row><cell></cell><cell></cell><cell>fatty acyl groups, such as</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitate, from modified</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cysteine residues in proteins</cell><cell></cell></row><row><cell></cell><cell></cell><cell>or peptides during lysosomal</cell><cell></cell></row><row><cell></cell><cell></cell><cell>degradation. It has a</cell><cell></cell></row><row><cell></cell><cell></cell><cell>preference for acyl chain</cell><cell></cell></row><row><cell></cell><cell></cell><cell>lengths of 14 to 18 carbons.</cell><cell></cell></row><row><cell></cell><cell></cell><cell>PPT1 frequently catalyzes</cell><cell></cell></row><row><cell></cell><cell></cell><cell>cysteine residues that</cell><cell></cell></row><row><cell></cell><cell></cell><cell>participate in</cell><cell></cell></row><row><cell></cell><cell></cell><cell>disulfide bonds.</cell><cell></cell></row><row><cell>PPT2</cell><cell>Lysosome</cell><cell>PPT2 exhibits the highest S-</cell><cell>-</cell></row><row><cell></cell><cell></cell><cell>thioesterase activity for the</cell><cell></cell></row><row><cell></cell><cell></cell><cell>acyl groups palmitic and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>myristic acid, followed by</cell><cell></cell></row><row><cell></cell><cell></cell><cell>other short-and long-chain</cell><cell></cell></row><row><cell></cell><cell></cell><cell>acyl substrates. However,</cell><cell></cell></row><row><cell></cell><cell></cell><cell>PPT2 is unable to remove</cell><cell></cell></row><row><cell></cell><cell></cell><cell>palmitate from peptides</cell><cell></cell></row><row><cell></cell><cell></cell><cell>or proteins.</cell><cell></cell></row><row><cell>ABHD17A</cell><cell>Cell membrane</cell><cell>ABHD17A exhibits</cell><cell>MAP6,</cell></row><row><cell></cell><cell></cell><cell>depalmitoylating activity</cell><cell>NRAS</cell></row><row><cell></cell><cell></cell><cell>towards NRAS and DLG4/</cell><cell></cell></row><row><cell></cell><cell></cell><cell>PSD95, and it may also have</cell><cell></cell></row><row><cell></cell><cell></cell><cell>depalmitoylating activity</cell><cell></cell></row><row><cell></cell><cell></cell><cell>towards MAP6.</cell><cell></cell></row><row><cell>ABHD17B</cell><cell>Cell membrane</cell><cell>ABHD17B demonstrates</cell><cell>DLG4/</cell></row><row><cell></cell><cell></cell><cell>depalmitoylating activity</cell><cell>PSD95,</cell></row><row><cell></cell><cell></cell><cell>towards DLG4/PSD95</cell><cell>GAP43</cell></row><row><cell></cell><cell></cell><cell>and GAP43.</cell><cell></cell></row><row><cell>ABHD17C</cell><cell>Cell membrane</cell><cell>ABHD17C hydrolyzes fatty</cell><cell>NRAS,</cell></row><row><cell></cell><cell></cell><cell>acids from S-acylated</cell><cell>DLG4/</cell></row><row><cell></cell><cell></cell><cell>cysteine residues in proteins,</cell><cell>PSD95</cell></row><row><cell></cell><cell></cell><cell>and it also exhibits</cell><cell></cell></row><row><cell></cell><cell></cell><cell>depalmitoylating activity</cell><cell></cell></row><row><cell></cell><cell></cell><cell>towards NRAS and</cell><cell></cell></row><row><cell></cell><cell></cell><cell>DLG4/PSD95.</cell><cell></cell></row></table></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_0"><p>Chen et al. 10.3389/fimmu.2024.1337478 Frontiers in Immunology frontiersin.org</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_1"><p>Frontiers in Immunology frontiersin.org</p></note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot" xml:id="foot_2"><p>10.3389/fimmu.2024.1337478 Frontiers in Immunology frontiersin.org</p></note>
		</body>
		<back>

			<div type="acknowledgement">
<div><head>Acknowledgments</head><p>The authors appreciate members of our laboratories for their kind suggestions.</p></div>
			</div>
			<div type="funding">
<div><head>Funding</head><p>The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the <rs type="funder">Major International (Regional)</rs> <rs type="programName">Joint Research Program</rs> of the <rs type="funder">National Natural Science Foundation of China</rs> (No. <rs type="grantNumber">81920108027</rs>), <rs type="funder">National Natural Science Foundation of China</rs> (No. <rs type="grantNumber">82271885</rs>), and <rs type="funder">Natural Science Foundation of Chongqing</rs> (No. <rs type="grantNumber">cstc2021jcyj-msxmX0111</rs>).</p></div>
			</div>
			<listOrg type="funding">
				<org type="funding" xml:id="_2B9J2P8">
					<orgName type="program" subtype="full">Joint Research Program</orgName>
				</org>
				<org type="funding" xml:id="_KVGSb5N">
					<idno type="grant-number">81920108027</idno>
				</org>
				<org type="funding" xml:id="_YK6rdn9">
					<idno type="grant-number">82271885</idno>
				</org>
				<org type="funding" xml:id="_fTwUxVd">
					<idno type="grant-number">cstc2021jcyj-msxmX0111</idno>
				</org>
			</listOrg>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conflict of interest</head><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p><p>The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Publisher's note</head><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Protein palmitoylation: Palmitoyltransferases and their specificity</title>
		<author>
			<persName><forename type="first">S</forename><surname>Tabaczar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Czogalla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Podkalicka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Biernatowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">F</forename><surname>Sikorski</surname></persName>
		</author>
		<idno type="DOI">10.1177/1535370217707732</idno>
	</analytic>
	<monogr>
		<title level="j">Exp Biol Med (Maywood)</title>
		<imprint>
			<biblScope unit="volume">242</biblScope>
			<biblScope unit="page" from="1150" to="1157" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">SwissPalm 2: protein S-palmitoylation database</title>
		<author>
			<persName><forename type="first">M</forename><surname>Blanc</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fpa</forename><surname>David</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Van Der Goot</surname></persName>
		</author>
		<idno type="DOI">10.1007/978-1-4939-9532-5_16</idno>
	</analytic>
	<monogr>
		<title level="j">Methods Mol Biol</title>
		<imprint>
			<biblScope unit="page" from="203" to="214" />
			<date type="published" when="2009">2019. 2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Function of protein S-palmitoylation in immunity and immune-related diseases</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Qin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Chu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2021.661202</idno>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">661202</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">S-palmitoylation as a functional regulator of proteins associated with cisplatin resistance in bladder cancer</title>
		<author>
			<persName><forename type="first">M</forename><surname>Shahid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">P</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.45640</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Biol Sci</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="2490" to="2505" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<monogr>
		<author>
			<persName><forename type="first">J</forename><surname>Charollais</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">G</forename><surname>Van Der Goot</surname></persName>
		</author>
		<title level="m">Palmitoylation of membrane proteins</title>
		<imprint/>
	</monogr>
	<note>Review</note>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title/>
		<idno type="DOI">10.1080/09687680802620369</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Membr Biol</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="55" to="66" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Protein lipidation in cell signaling and diseases: function, regulation, and therapeutic opportunities</title>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Jarugumilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chembiol.2018.05.003</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Chem Biol</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="817" to="831" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Insights into the post-translational modification and its emerging role in shaping the tumor microenvironment</title>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">K</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-021-00825-8</idno>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct Target Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">422</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Protein acylation: mechanisms, biological functions and therapeutic targets</title>
		<author>
			<persName><forename type="first">S</forename><surname>Shang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hua</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-022-01245-y</idno>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct Target Ther</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">396</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Immune checkpoint inhibitors in cancer therapy</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Shiravand</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Khodadadi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Sma</forename><surname>Kashani</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">R</forename><surname>Hosseini-Fard</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Hosseini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Sadeghirad</surname></persName>
		</author>
		<idno type="DOI">10.3390/curroncol29050247</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="3044" to="3060" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">A decade of immune-checkpoint inhibitors in cancer therapy</title>
		<author>
			<persName><forename type="first">C</forename><surname>Robert</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-020-17670-y</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">3801</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Lipid metabolism and cancer</title>
		<author>
			<persName><forename type="first">X</forename><surname>Bian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xing</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lu</surname></persName>
		</author>
		<idno type="DOI">10.1084/jem.20201606</idno>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="page">218</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">Protein palmitoylation and cancer</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">J</forename><surname>Ko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Dixon</surname></persName>
		</author>
		<idno type="DOI">10.15252/embr.201846666</idno>
	</analytic>
	<monogr>
		<title level="j">EMBO Rep</title>
		<imprint>
			<biblScope unit="page">19</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Human DHHC proteins: a spotlight on the hidden player of palmitoylation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Korycka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lach</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Heger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Boguslawska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wolny</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Toporkiewicz</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejcb.2011.09.013</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">91</biblScope>
			<biblScope unit="page" from="107" to="117" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Zdhhc2 is essential for plasmacytoid dendritic cells mediated inflammatory response in psoriasis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2020.607442</idno>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">607442</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Inhibitors of DHHC family proteins</title>
		<author>
			<persName><forename type="first">T</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Delalande</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">C</forename><surname>Dickinson</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cbpa.2021.07.002</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Chem Biol</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="118" to="125" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Substrate recruitment by zDHHC protein acyltransferases</title>
		<author>
			<persName><forename type="first">Mip</forename><surname>Malgapo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Linder</surname></persName>
		</author>
		<idno type="DOI">10.1098/rsob.210026</idno>
	</analytic>
	<monogr>
		<title level="j">Open Biol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page">210026</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Zinc co-ordination by the DHHC cysteine-rich domain of the palmitoyltransferase Swf1</title>
		<author>
			<persName><forename type="first">A</forename><surname>Gonzalez Montoro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Quiroga</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Valdez</forename><surname>Taubas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename></persName>
		</author>
		<idno type="DOI">10.1042/BJ20121693</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem J</title>
		<imprint>
			<biblScope unit="volume">454</biblScope>
			<biblScope unit="page" from="427" to="435" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The Golgi S-acylation machinery comprises zDHHC enzymes with major differences in substrate affinity and S-acylation activity</title>
		<author>
			<persName><forename type="first">K</forename><surname>Lemonidis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">A</forename><surname>Gorleku</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Sanchez-Perez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Grefen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Chamberlain</surname></persName>
		</author>
		<idno type="DOI">10.1091/mbc.E14-06-1169</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Biol Cell</title>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="page" from="3870" to="3883" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">The physiology of protein S-acylation</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">H</forename><surname>Chamberlain</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Shipston</surname></persName>
		</author>
		<idno type="DOI">10.1152/physrev.00032.2014</idno>
	</analytic>
	<monogr>
		<title level="j">Physiol Rev</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="341" to="376" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Structural and genomic decoding of human and plant myristoylomes reveals a definitive recognition pattern</title>
		<author>
			<persName><forename type="first">B</forename><surname>Castrec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Dian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ciccone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Ebert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">V</forename><surname>Bienvenut</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Le</forename><surname>Caer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J-P</forename></persName>
		</author>
		<idno type="DOI">10.1038/s41589-018-0077-5</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="671" to="679" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Identification of a Ras palmitoyltransferase in Saccharomyces cerevisiae</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lobo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">K</forename><surname>Greentree</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Linder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Deschenes</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m206573200</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">277</biblScope>
			<biblScope unit="page" from="41268" to="41273" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Fatty acyl recognition and transfer by an integral membrane S-acyltransferase</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Rana</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Verardi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Rajashankar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Banerjee</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.aao6326</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="page">359</biblScope>
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Protein lipidation by palmitoylation and myristoylation in cancer</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Fhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ali</surname></persName>
		</author>
		<idno type="DOI">10.3389/fcell.2021.673647</idno>
	</analytic>
	<monogr>
		<title level="j">Front Cell Dev Biol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page">673647</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">A cytoplasmic acyl-protein thioesterase that removes palmitate from G protein alpha subunits and p21(RAS)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Duncan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">G</forename><surname>Gilman</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.273.25.15830</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">273</biblScope>
			<biblScope unit="page" from="15830" to="15837" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Molecular mechanism for isoform-selective inhibition of acyl protein thioesterases 1 and 2 (APT1 and APT2)</title>
		<author>
			<persName><forename type="first">L</forename><surname>Abrami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Audagnotto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ho</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Marcaida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><forename type="middle">S</forename><surname>Mesquita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">U</forename><surname>Anwar</surname></persName>
		</author>
		<idno type="DOI">10.1021/acschembio.6b00720</idno>
		<idno>doi: 10.1021/acschembio.6b00720</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3374" to="3382" />
			<date type="published" when="2016">2021. 2016</date>
		</imprint>
	</monogr>
	<note>ACS Chem Biol</note>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Dynamic palmitoylation links cytosol-membrane shuttling of acyl-protein thioesterase-1 and acyl-protein thioesterase-2 with that of proto-oncogene H-ras product and growthassociated protein-43</title>
		<author>
			<persName><forename type="first">E</forename><surname>Kong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Chandra</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Sarkar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Bagh</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M112.421073</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="9112" to="9125" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Identification of substrates of palmitoyl protein thioesterase 1 highlights roles of depalmitoylation in disulfide bond formation and synaptic function</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">L</forename><surname>Gorenberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Massaro</forename><surname>Tieze</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Yucel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">R</forename><surname>Chou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Wirak</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1371/journal.pbio.3001590</idno>
	</analytic>
	<monogr>
		<title level="j">PloS Biol</title>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="page">3001590</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Targeting the Ras palmitoylation/ depalmitoylation cycle in cancer</title>
		<author>
			<persName><forename type="first">Dts</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">G</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conibear</surname></persName>
		</author>
		<idno type="DOI">10.1042/BST20160303</idno>
	</analytic>
	<monogr>
		<title level="j">Biochem Soc Trans</title>
		<imprint>
			<biblScope unit="volume">45</biblScope>
			<biblScope unit="page" from="913" to="921" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Site-specific deacylation by ABHD17a controls BK channel splice variant activity</title>
		<author>
			<persName><forename type="first">H</forename><surname>Mcclafferty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Runciman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Shipston</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.RA120.015349</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">295</biblScope>
			<biblScope unit="page" from="16487" to="16496" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">ABHD17 proteins are novel protein depalmitoylases that regulate N-Ras palmitate turnover and subcellular localization</title>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">T</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Conibear</surname></persName>
		</author>
		<idno type="DOI">10.7554/eLife.11306</idno>
	</analytic>
	<monogr>
		<title level="j">Elife</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page">11306</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Identification and dynamics of the human ZDHHC16-ZDHHC6 palmitoylation cascade</title>
		<author>
			<persName><forename type="first">L</forename><surname>Abrami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Dallavilla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Sandoz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Demir</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kunz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Savoglidis</surname></persName>
		</author>
		<idno type="DOI">10.7554/eLife.27826</idno>
	</analytic>
	<monogr>
		<title level="j">Elife</title>
		<imprint>
			<biblScope unit="page">6</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Palmitoylation stabilizes PD-L1 to promote breast tumor growth</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">M</forename><surname>Hsu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">W</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hsu</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41422-018-0124-5</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Res</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="page" from="83" to="86" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Palmitoylation of oncogenic NRAS is essential for leukemogenesis</title>
		<author>
			<persName><forename type="first">B</forename><surname>Cuiffo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ren</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2009-03-213876</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">115</biblScope>
			<biblScope unit="page" from="3598" to="3605" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Palmitoylacyltransferase Zdhhc9 inactivation mitigates leukemogenic potential of oncogenic Nras</title>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Jiao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1038/leu.2015.293</idno>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page" from="1225" to="1228" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Protein palmitoylation and subcellular trafficking</title>
		<author>
			<persName><forename type="first">C</forename><surname>Aicart-Ramos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Valero</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rodriguez-Crespo</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbamem.2011.07.009</idno>
	</analytic>
	<monogr>
		<title level="j">Biochim Biophys Acta</title>
		<imprint>
			<biblScope unit="volume">1808</biblScope>
			<biblScope unit="page" from="2981" to="2994" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Palmitoylation as a key regulator of ras localization and function</title>
		<author>
			<persName><forename type="first">C</forename><surname>Busquets-Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Triola</surname></persName>
		</author>
		<idno type="DOI">10.3389/fmolb.2021.659861</idno>
	</analytic>
	<monogr>
		<title level="j">Front Mol Biosci</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page">659861</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Epidermal growth factor receptor cell proliferation signaling pathways</title>
		<author>
			<persName><forename type="first">P</forename><surname>Wee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers9050052</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2017">2017</date>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Inhibition of DHHC20-mediated EGFR palmitoylation creates a dependence on EGFR signaling</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">B</forename><surname>Runkle</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Kharbanda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Stypulkowski</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Cao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Wang</forename><forename type="middle">W</forename><surname>Garcia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">A</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.molcel.2016.04.003</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Cell</title>
		<imprint>
			<biblScope unit="volume">62</biblScope>
			<biblScope unit="page" from="385" to="396" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Menendez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lupu</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrc2222</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Cancer</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="763" to="777" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells</title>
		<author>
			<persName><forename type="first">A</forename><surname>Vazquez-Martin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Colomer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Brunet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Lupu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Menendez</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1365-2184.2007.00498.x</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Prolif</title>
		<imprint>
			<biblScope unit="volume">41</biblScope>
			<biblScope unit="page" from="59" to="85" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Targeting EGFRdependent tumors by disrupting an ARF6-mediated sorting system</title>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">F</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">X</forename><surname>Zhuang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">L</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-022-33788-7</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Commun</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">6004</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Dong</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Zi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41420-023-01770-x</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Discov</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">41</biblScope>
			<date type="published" when="2024">2024</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">EGF inhibits constitutive internalization and palmitoylation-dependent degradation of membrane-spanning procancer CDCP1 promoting its availability on the cell surface</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">N</forename><surname>Adams</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">S</forename><surname>Harrington</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">M</forename><surname>Davies</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Wallace</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">P</forename><surname>Chetty</surname></persName>
		</author>
		<idno type="DOI">10.1038/onc.2014.88</idno>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">34</biblScope>
			<biblScope unit="page" from="1375" to="1383" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Claudin-3 gene silencing with siRNA suppresses ovarian tumor growth and metastasis</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">H</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Goldberg</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Love</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Bumcrot</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.0813348106</idno>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="3426" to="3430" />
			<date type="published" when="2009">2009</date>
			<pubPlace>USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">ZDHHC22-mediated mTOR palmitoylation restrains breast cancer growth and endocrine therapy resistance</title>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Dai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yi</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.70544</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Biol Sci</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="2833" to="2850" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">ZDHHC2-mediated AGK palmitoylation activates AKT-mTOR signaling to reduce sunitinib sensitivity in renal cell carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">X</forename></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.CAN-22-3105</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">83</biblScope>
			<biblScope unit="page" from="2034" to="2051" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">S-palmitoylation of PCSK9 induces sorafenib resistance in liver cancer by activating the PI3K/AKT pathway</title>
		<author>
			<persName><forename type="first">A</forename><surname>Bhattacharya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Chowdhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Chaudhury</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Pc ;</forename><surname>Shukla</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Meng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.celrep.2022.111194</idno>
		<idno>doi: 10.1016/j.celrep.2022.111194</idno>
	</analytic>
	<monogr>
		<title level="m">Proprotein convertase subtilisin/kexin type 9</title>
		<imprint>
			<date type="published" when="2021">2021. 2022</date>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page">111194</biblScope>
		</imprint>
	</monogr>
	<note>Cell Rep</note>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Targeting PCSK9: a promising adjuvant strategy in cancer immunotherapy</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">R</forename><surname>Almeida</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">H</forename><surname>Ferreira</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><forename type="middle">F</forename><surname>Duarte</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41392-021-00530-6</idno>
	</analytic>
	<monogr>
		<title level="j">Signal Transduct Target Ther</title>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">111</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">Cancer cells escape p53&apos;s tumor suppression through ablation of ZDHHC1-mediated p53 palmitoylation</title>
		<author>
			<persName><forename type="first">J</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Feng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Le</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Xiang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41388-021-01949-5</idno>
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<imprint>
			<biblScope unit="volume">40</biblScope>
			<biblScope unit="page" from="5416" to="5426" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Apoptosis in cancer: from pathogenesis to treatment</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Wong</surname></persName>
		</author>
		<idno type="DOI">10.1186/1756-9966-30-87</idno>
	</analytic>
	<monogr>
		<title level="j">J Exp Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="page">87</biblScope>
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b51">
	<analytic>
		<title level="a" type="main">Analysis of the brain palmitoylproteome using both acyl-biotin exchange and acyl-resin-assisted capture methods</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">J</forename><surname>Edmonds</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Geary</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Doherty</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Morgan</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41598-017-03562-7</idno>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">3299</biblScope>
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b52">
	<analytic>
		<title level="a" type="main">Palmitoylation is required for TNF-R1 signaling</title>
		<author>
			<persName><forename type="first">P</forename><surname>Zingler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Sarchen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Glatter</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Caning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Saggau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">S</forename><surname>Kathayat</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12964-019-0405-8</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Commun Signal</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page">90</biblScope>
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b53">
	<analytic>
		<title level="a" type="main">Fas palmitoylation by the palmitoyl acyltransferase DHHC7 regulates Fas stability</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rossin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Durivault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Chakhtoura-Feghali</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Lounnas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Gagnoux-Palacios</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">O</forename><surname>Hueber</surname></persName>
		</author>
		<idno type="DOI">10.1038/cdd.2014.153</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="page" from="643" to="653" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b54">
	<analytic>
		<title level="a" type="main">Fas-fas ligand: checkpoint of T cell functions in multiple sclerosis</title>
		<author>
			<persName><forename type="first">E</forename><surname>Volpe</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Sambucci</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Battistini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Borsellino</surname></persName>
		</author>
		<idno type="DOI">10.3389/fimmu.2016.00382</idno>
	</analytic>
	<monogr>
		<title level="j">Front Immunol</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page">382</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b55">
	<analytic>
		<title level="a" type="main">Palmitoylation of human FasL modulates its cell death-inducing function</title>
		<author>
			<persName><forename type="first">F</forename><surname>Guardiola-Serrano</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Rossin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Cahuzac</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Luckerath</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Melzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mailfert</surname></persName>
		</author>
		<idno type="DOI">10.1038/cddis.2010.62</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Dis</title>
		<imprint>
			<biblScope unit="volume">1</biblScope>
			<biblScope unit="page">88</biblScope>
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b56">
	<analytic>
		<title level="a" type="main">Palmitoylation is required for efficient Fas cell death signaling</title>
		<author>
			<persName><forename type="first">K</forename><surname>Chakrabandhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Herincs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Huault</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Dost</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Peng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Conchonaud</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.emboj.7601456</idno>
	</analytic>
	<monogr>
		<title level="j">EMBO J</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="209" to="220" />
			<date type="published" when="2007">2007</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b57">
	<analytic>
		<title level="a" type="main">Rapid and transient palmitoylation of the tyrosine kinase Lck mediates Fas signaling</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Akimzhanov</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boehning</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1509929112</idno>
	</analytic>
	<monogr>
		<title level="j">Proc Natl Acad Sci</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="page" from="11876" to="11880" />
			<date type="published" when="2015">2015</date>
			<pubPlace>USA</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b58">
	<analytic>
		<title level="a" type="main">Death receptor 6 (DR6) is required for mouse B16 tumor angiogenesis via the NF-kappaB, P38 MAPK and STAT3 pathways</title>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ge</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Shi</surname></persName>
		</author>
		<idno type="DOI">10.1038/oncsis.2016.9</idno>
	</analytic>
	<monogr>
		<title level="j">Oncogenesis</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">206</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b59">
	<analytic>
		<title level="a" type="main">Palmitoylation of caspase-6 by HIP14 regulates its activation</title>
		<author>
			<persName><forename type="first">N</forename><forename type="middle">H</forename><surname>Skotte</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Sanders</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">R</forename><surname>Singaraja</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">E</forename><surname>Ehrnhoefer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Vaid</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Qiu</surname></persName>
		</author>
		<idno type="DOI">10.1038/cdd.2016.139</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death Differ</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="433" to="444" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b60">
	<analytic>
		<title level="a" type="main">The role of BCL-2 family proteins in regulating apoptosis and cancer therapy</title>
		<author>
			<persName><forename type="first">S</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2022.985363</idno>
	</analytic>
	<monogr>
		<title level="j">Front Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">985363</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b61">
	<analytic>
		<title level="a" type="main">Tetraspanins: integrating cell surface receptors to functional microdomains in homeostasis and disease</title>
		<author>
			<persName><forename type="first">D</forename><surname>Kummer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steinbacher</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Schwietzer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Tholmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Ebnet</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00430-020-00673-3</idno>
	</analytic>
	<monogr>
		<title level="j">Med Microbiol Immunol</title>
		<imprint>
			<biblScope unit="volume">209</biblScope>
			<biblScope unit="page" from="397" to="405" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b62">
	<analytic>
		<title level="a" type="main">Palmitoylation supports assembly and function of integrin-tetraspanin complexes</title>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">V</forename><surname>Kovalenko</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Tang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Claas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">S</forename><surname>Stipp</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hemler</surname></persName>
		</author>
		<idno type="DOI">10.1083/jcb.200404100</idno>
	</analytic>
	<monogr>
		<title level="j">J Cell Biol</title>
		<imprint>
			<biblScope unit="volume">167</biblScope>
			<biblScope unit="page" from="1231" to="1240" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b63">
	<analytic>
		<title level="a" type="main">Clinical significance of the integrin alpha6beta4 in human Malignancies</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Stewart</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O'</forename><surname>Connor</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename></persName>
		</author>
		<idno type="DOI">10.1038/labinvest.2015.82</idno>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">95</biblScope>
			<biblScope unit="page" from="976" to="986" />
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b64">
	<analytic>
		<title level="a" type="main">Overexpression of RAB27A in oral squamous cell carcinoma promotes tumor migration and invasion via modulation of EGFR membrane stability</title>
		<author>
			<persName><forename type="first">J</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">G</forename><surname>Ren</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">F</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">H</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><forename type="middle">Y</forename><surname>Fu</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms241713103</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="page">24</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b65">
	<analytic>
		<title level="a" type="main">Roles of integrin alpha6beta4 glycosylation in cancer</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Kariya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Kariya</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Gu</surname></persName>
		</author>
		<idno type="DOI">10.3390/cancers9070079</idno>
	</analytic>
	<monogr>
		<title level="j">Cancers</title>
		<imprint>
			<biblScope unit="page">9</biblScope>
			<date type="published" when="2017">2017</date>
			<pubPlace>Basel</pubPlace>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b66">
	<analytic>
		<title level="a" type="main">Palmitoylation by DHHC3 is critical for the function, expression, and stability of integrin alpha6beta4</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Rabinovitz</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">E</forename><surname>Hemler</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00018-012-0924-6</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Life Sci</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="2233" to="2244" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b67">
	<analytic>
		<title level="a" type="main">Flotillins: at the intersection of protein S-palmitoylation and lipid-mediated signaling</title>
		<author>
			<persName><forename type="first">K</forename><surname>Kwiatkowska</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><forename type="middle">V</forename><surname>Matveichuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fronk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ciesielska</surname></persName>
		</author>
		<idno type="DOI">10.3390/ijms21072283</idno>
	</analytic>
	<monogr>
		<title level="j">Int J Mol Sci</title>
		<imprint>
			<biblScope unit="page">21</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b68">
	<analytic>
		<title level="a" type="main">Overexpression of flotillin-1 is involved in proliferation and recurrence of bladder transitional cell carcinoma</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Guan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ai</forename><forename type="middle">X</forename></persName>
		</author>
		<idno type="DOI">10.3892/or.2014.3221</idno>
	</analytic>
	<monogr>
		<title level="j">Oncol Rep</title>
		<imprint>
			<biblScope unit="volume">32</biblScope>
			<biblScope unit="page" from="748" to="754" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b69">
	<analytic>
		<title level="a" type="main">Flotilin-1 promotes the tumorigenicity and progression of Malignant phenotype in human lung adenocarcinoma</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">Y</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">J</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Bi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">Y</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.1080/15384047.2017.1360445</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Biol Ther</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="715" to="722" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b70">
	<analytic>
		<title level="a" type="main">MUC1 and metastatic cancer: expression, function and therapeutic targeting</title>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">M</forename><surname>Horm</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Ja ;</forename><surname>Schroeder</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">L</forename><surname>Kinlough</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Mcmahan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">A</forename><surname>Poland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">B</forename><surname>Bruns</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">L</forename><surname>Harkleroad</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">J</forename><surname>Stremple</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M512996200</idno>
		<idno>doi: 10.1074/jbc.M512996200</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Adh Migr</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="12112" to="12122" />
			<date type="published" when="2006">2013. 2006</date>
		</imprint>
	</monogr>
	<note>J Biol Chem</note>
</biblStruct>

<biblStruct xml:id="b71">
	<analytic>
		<title level="a" type="main">Palmitoylation of CCR5 is critical for receptor trafficking and efficient activation of intracellular signaling pathways</title>
		<author>
			<persName><forename type="first">M</forename><surname>Iizuka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Nakanishi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Fuchinoue</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Maeda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Murakami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Obana</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.M100583200</idno>
		<idno>doi: 10.1074/ jbc.M100583200</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">106</biblScope>
			<biblScope unit="page" from="23795" to="23804" />
			<date type="published" when="2001">2015. 2001</date>
		</imprint>
	</monogr>
	<note>Cancer Sci</note>
</biblStruct>

<biblStruct xml:id="b72">
	<analytic>
		<title level="a" type="main">EZH2-triggered methylation of SMAD3 promotes its activation and tumor metastasis</title>
		<author>
			<persName><forename type="first">C</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Wu</surname></persName>
		</author>
		<idno type="DOI">10.1172/JCI152394</idno>
	</analytic>
	<monogr>
		<title level="j">J Clin Invest</title>
		<imprint>
			<biblScope unit="page">132</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b73">
	<analytic>
		<title level="a" type="main">Heterogeneity of subsets in glioblastoma mediated by Smad3 palmitoylation</title>
		<author>
			<persName><forename type="first">X</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Fan</forename><forename type="middle">J</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Niu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename></persName>
		</author>
		<idno type="DOI">10.1038/s41389-021-00361-8</idno>
	</analytic>
	<monogr>
		<title level="j">Oncogenesis</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">72</biblScope>
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b74">
	<analytic>
		<title level="a" type="main">Dietary palmitate cooperates with Src kinase to promote prostate tumor progression</title>
		<author>
			<persName><forename type="first">S</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Beharry</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Bai</surname></persName>
		</author>
		<idno type="DOI">10.1002/pros.23796</idno>
	</analytic>
	<monogr>
		<title level="j">Prostate</title>
		<imprint>
			<biblScope unit="volume">79</biblScope>
			<biblScope unit="page" from="896" to="908" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b75">
	<analytic>
		<title level="a" type="main">DHHC9-mediated GLUT1 Spalmitoylation promotes glioblastoma glycolysis and tumorigenesis</title>
		<author>
			<persName><forename type="first">K</forename><surname>Adekola</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">T</forename><surname>Rosen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M ;</forename><surname>Shanmugam</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Ren</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41467-021-26180-4</idno>
		<idno>doi: 10.1038/s41467-021-26180-4</idno>
	</analytic>
	<monogr>
		<title level="j">Curr Opin Oncol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page">5872</biblScope>
			<date type="published" when="2012">2012. 2021</date>
		</imprint>
	</monogr>
	<note>Nat Commun</note>
</biblStruct>

<biblStruct xml:id="b76">
	<analytic>
		<title level="a" type="main">Palmitoylation of MDH2 by ZDHHC18 activates mitochondrial respiration and accelerates ovarian cancer growth</title>
		<author>
			<persName><forename type="first">X</forename><surname>Pei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">Z</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">Y</forename><surname>Fang</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11427-021-2048-2</idno>
	</analytic>
	<monogr>
		<title level="j">Sci China Life Sci</title>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="page" from="2017" to="2030" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b77">
	<analytic>
		<title level="a" type="main">Adenylate kinase 2 expression and addiction in T-ALL</title>
		<author>
			<persName><forename type="first">N</forename><surname>Maslah</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Latiri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">V</forename><surname>Asnafi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Feroul</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Bedjaoui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Steimle</surname></persName>
		</author>
		<idno type="DOI">10.1182/bloodadvances.2020002700</idno>
	</analytic>
	<monogr>
		<title level="j">Blood Adv</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="700" to="710" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b78">
	<analytic>
		<title level="a" type="main">The palmitoyltransferase ZDHHC21 regulates oxidative phosphorylation to induce differentiation block and stemness in AML</title>
		<author>
			<persName><forename type="first">X</forename><surname>Shao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Xia</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood.2022019056</idno>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">142</biblScope>
			<biblScope unit="page" from="365" to="381" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b79">
	<analytic>
		<title level="a" type="main">Lipid metabolism in cancer: New perspectives and emerging mechanisms</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">A</forename><surname>Broadfield</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Pane</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Talebi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">V</forename><surname>Swinnen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Fendt</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.devcel.2021.04.013</idno>
	</analytic>
	<monogr>
		<title level="j">Dev Cell</title>
		<imprint>
			<biblScope unit="volume">56</biblScope>
			<biblScope unit="page" from="1363" to="1393" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b80">
	<analytic>
		<title level="a" type="main">CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">L</forename><surname>Silverstein</surname></persName>
		</author>
		<idno type="DOI">10.1084/jem.20211314</idno>
	</analytic>
	<monogr>
		<title level="j">J Exp Med</title>
		<imprint>
			<biblScope unit="page">219</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b81">
	<analytic>
		<title level="a" type="main">Inhibition of fatty acid translocase (FAT/CD36) palmitoylation enhances hepatic fatty acid beta-oxidation by increasing its localization to mitochondria and interaction with long-chain Acyl-CoA synthetase 1</title>
		<author>
			<persName><forename type="first">S</forename><surname>Zeng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>You</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1089/ars.2021.0157</idno>
	</analytic>
	<monogr>
		<title level="j">Antioxid Redox Signal</title>
		<imprint>
			<biblScope unit="volume">36</biblScope>
			<biblScope unit="page" from="1081" to="1100" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b82">
	<analytic>
		<title level="a" type="main">CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis</title>
		<author>
			<persName><forename type="first">L</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Zhong</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jhep.2018.04.006</idno>
	</analytic>
	<monogr>
		<title level="j">J Hepatol</title>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="page" from="705" to="717" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b83">
	<analytic>
		<title level="a" type="main">DHHC4 and DHHC5 facilitate fatty acid uptake by palmitoylating and targeting CD36 to the plasma membrane</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">W</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Guo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">H</forename><surname>Sun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><forename type="middle">Y</forename><surname>Lai</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.celrep.2018.12.022</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Rep</title>
		<imprint>
			<biblScope unit="volume">26</biblScope>
			<biblScope unit="page" from="209" to="221" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b84">
	<analytic>
		<title level="a" type="main">Protein cysteine palmitoylation in immunity and inflammation</title>
		<author>
			<persName><forename type="first">H</forename><surname>Lin</surname></persName>
		</author>
		<idno type="DOI">10.1111/febs.15728</idno>
	</analytic>
	<monogr>
		<title level="j">FEBS J</title>
		<imprint>
			<biblScope unit="volume">288</biblScope>
			<biblScope unit="page" from="7043" to="7059" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b85">
	<analytic>
		<title level="a" type="main">IFNgamma: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">B</forename><surname>Ivashkiv</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41577-018-0029-z</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Immunol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="545" to="558" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b86">
	<analytic>
		<title level="a" type="main">IFNgamma signaling integrity in colorectal cancer immunity and immunotherapy</title>
		<author>
			<persName><forename type="first">W</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">L</forename><surname>Frankel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Zou</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41423-021-00735-3</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Mol Immunol</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="page" from="23" to="32" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b87">
	<analytic>
		<title level="a" type="main">Loss of optineurin drives cancer immune evasion via palmitoylation-dependent IFNGR1 lysosomal sorting and degradation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Hua</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-20-1571</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Discovery</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="page" from="1826" to="1843" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b88">
	<analytic>
		<title level="a" type="main">The role of NOD1 and NOD2 in host defense against chlamydial infection</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Lei</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1093/femsle/fnw170</idno>
	</analytic>
	<monogr>
		<title level="j">FEMS Microbiol Lett</title>
		<imprint>
			<biblScope unit="page">363</biblScope>
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b89">
	<analytic>
		<title level="a" type="main">Palmitoylation of NOD1 and NOD2 is required for bacterial sensing</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Lu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Coyaud</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Selvabaskaran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.aau6391</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<imprint>
			<biblScope unit="volume">366</biblScope>
			<biblScope unit="page" from="460" to="467" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b90">
	<analytic>
		<title level="a" type="main">Toll-like receptor 4 (TLR4) inhibitors: Current research and prospective</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Bao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Xiao</forename><forename type="middle">W</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmech.2022.114291</idno>
	</analytic>
	<monogr>
		<title level="j">Eur J Med Chem</title>
		<imprint>
			<biblScope unit="volume">235</biblScope>
			<biblScope unit="page">114291</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b91">
	<analytic>
		<title level="a" type="main">Myeloid differentiation primary response protein 88 (MyD88): the central hub of TLR/IL-1R signaling</title>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Liang</surname></persName>
		</author>
		<idno type="DOI">10.1021/acs.jmedchem.0c00884</idno>
	</analytic>
	<monogr>
		<title level="j">J Med Chem</title>
		<imprint>
			<biblScope unit="volume">63</biblScope>
			<biblScope unit="page" from="13316" to="13329" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b92">
	<analytic>
		<title level="a" type="main">Toll-like receptor mediated inflammation requires FASN-dependent MYD88 palmitoylation</title>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">E</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">K</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">D</forename><surname>Jang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Hwang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Jin</forename><forename type="middle">S</forename></persName>
		</author>
		<idno type="DOI">10.1038/s41589-019-0344-0</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="907" to="916" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b93">
	<analytic>
		<title level="a" type="main">Interferon-independent activities of mammalian STING mediate antiviral response and tumor immune evasion</title>
		<author>
			<persName><forename type="first">J</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Dobbs</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Yan</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.immuni.2020.06.009</idno>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">53</biblScope>
			<biblScope unit="page" from="115" to="126" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b94">
	<analytic>
		<title level="a" type="main">STING suppresses mitochondrial VDAC2 to govern RCC growth independent of innate immunity</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Du</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">W</forename><surname>Cloer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Mei</surname></persName>
		</author>
		<idno type="DOI">10.1002/advs.202203718</idno>
	</analytic>
	<monogr>
		<title level="j">Adv Sci (Weinh)</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<biblScope unit="page">2203718</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b95">
	<analytic>
		<title level="a" type="main">Targeting STING with covalent small-molecule inhibitors</title>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">M</forename><surname>Haag</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">F</forename><surname>Gulen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Reymond</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gibelin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Abrami</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Decout</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41586-018-0287-8</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">559</biblScope>
			<biblScope unit="page" from="269" to="273" />
			<date type="published" when="2018">2018</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b96">
	<analytic>
		<title level="a" type="main">Quantitative analysis of the human T cell palmitome</title>
		<author>
			<persName><forename type="first">E</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Kuropka</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kliche</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Brugger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Krause</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Freund</surname></persName>
		</author>
		<idno type="DOI">10.1038/srep11598</idno>
	</analytic>
	<monogr>
		<title level="j">Sci Rep</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page">11598</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b97">
	<analytic>
		<title level="a" type="main">Dynamic palmitoylation events following T-cell receptor signaling</title>
		<author>
			<persName><forename type="first">E</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Wegner</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">E</forename><surname>Zucchetti</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Alvaro-Benito</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Kliche</surname></persName>
		</author>
		<idno type="DOI">10.1038/s42003-020-1063-5</idno>
	</analytic>
	<monogr>
		<title level="j">Commun Biol</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page">368</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b98">
	<analytic>
		<title level="a" type="main">Structural basis for activation of ZAP-70 by phosphorylation of the SH2-kinase linker</title>
		<author>
			<persName><forename type="first">Q</forename><surname>Yan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Barros</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">R</forename><surname>Visperas</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Deindl</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">A</forename><surname>Kadlecek</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Weiss</surname></persName>
		</author>
		<idno type="DOI">10.1128/MCB.01637-12</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Cell Biol</title>
		<imprint>
			<biblScope unit="volume">33</biblScope>
			<biblScope unit="page" from="2188" to="2201" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b99">
	<analytic>
		<title level="a" type="main">Palmitoylation of ligands, receptors, and intracellular signaling molecules</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">D</forename><surname>Resh</surname></persName>
		</author>
		<idno type="DOI">10.1126/stke.3592006re14</idno>
	</analytic>
	<monogr>
		<title level="j">Sci STKE</title>
		<imprint>
			<biblScope unit="page">14</biblScope>
			<date type="published" when="2006">2006. 2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b100">
	<analytic>
		<title level="a" type="main">DHHC2 is a protein S-acyltransferase for lck</title>
		<author>
			<persName><forename type="first">R</forename><surname>Zeidman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Buckland</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Cebecauer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Eissmann</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">M</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">I</forename><surname>Magee</surname></persName>
		</author>
		<idno type="DOI">10.3109/09687688.2011.630682</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Membr Biol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="page" from="473" to="486" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b101">
	<analytic>
		<title level="a" type="main">Regulation of T cell receptor signaling by protein acyltransferase DHHC21</title>
		<author>
			<persName><forename type="first">Y</forename><surname>Fan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Shayahati</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Tewari</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Boehning</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Akimzhanov</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11033-020-05691-1</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Biol Rep</title>
		<imprint>
			<biblScope unit="volume">47</biblScope>
			<biblScope unit="page" from="6471" to="6478" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b102">
	<analytic>
		<title level="a" type="main">Phospholipase Cgamma1 (PLCG1) overexpression is associated with tumor growth and poor survival in IDH wild-type lower-grade gliomas in adult patients</title>
		<author>
			<persName><forename type="first">T</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Tang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41374-021-00682-7</idno>
	</analytic>
	<monogr>
		<title level="j">Lab Invest</title>
		<imprint>
			<biblScope unit="volume">102</biblScope>
			<biblScope unit="page" from="143" to="153" />
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b103">
	<analytic>
		<title level="a" type="main">LAT palmitoylation: its essential role in membrane microdomain targeting and tyrosine phosphorylation during T cell activation</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Trible</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Samelson</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1074-7613(00)80606-8</idno>
	</analytic>
	<monogr>
		<title level="j">Immunity</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="page" from="239" to="246" />
			<date type="published" when="1998">1998</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b104">
	<analytic>
		<title level="a" type="main">The role of IL-6/JAK2/STAT3 signaling pathway in cancers</title>
		<author>
			<persName><forename type="first">B</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Lang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.3389/fonc.2022.1023177</idno>
	</analytic>
	<monogr>
		<title level="j">Front Oncol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page">1023177</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b105">
	<analytic>
		<title level="a" type="main">A STAT3 palmitoylation cycle promotes T(H)17 differentiation and colitis</title>
		<author>
			<persName><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Yang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">P</forename><surname>Komaniecki</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41586-020-2799-2</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">586</biblScope>
			<biblScope unit="page" from="434" to="439" />
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b106">
	<analytic>
		<title level="a" type="main">PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Wolchok</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1126/scitranslmed.aad7118</idno>
	</analytic>
	<monogr>
		<title level="j">Sci Transl Med</title>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="page" from="328" to="332" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b107">
	<analytic>
		<title level="a" type="main">Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Shi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Brosseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41551-019-0375-6</idno>
	</analytic>
	<monogr>
		<title level="j">Nat BioMed Eng</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="306" to="317" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b108">
	<analytic>
		<title level="a" type="main">A peptidic inhibitor for PD-1 palmitoylation targets its expression and functions</title>
		<author>
			<persName><forename type="first">H</forename><surname>Yao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">P</forename><surname>Brosseau</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1039/d0cb00157k</idno>
	</analytic>
	<monogr>
		<title level="j">RSC Chem Biol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="192" to="205" />
			<date type="published" when="2021">2021</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b109">
	<analytic>
		<title level="a" type="main">Development of a novel high-throughput screen for the identification of new inhibitors of protein S-acylation</title>
		<author>
			<persName><forename type="first">C</forename><surname>Salaun</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><surname>Takizawa</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Galindo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">R</forename><surname>Munro</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Mclellan</surname></persName>
		</author>
		<author>
			<persName><forename type="first">I</forename><surname>Sugimoto</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.jbc.2022.102469</idno>
	</analytic>
	<monogr>
		<title level="j">J Biol Chem</title>
		<imprint>
			<biblScope unit="volume">298</biblScope>
			<biblScope unit="page">102469</biblScope>
			<date type="published" when="2022">2022</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b110">
	<analytic>
		<title level="a" type="main">Inhibition of de novo palmitate synthesis by fatty acid synthase induces apoptosis in tumor cells by remodeling cell membranes, inhibiting signaling pathways, and reprogramming gene expression</title>
		<author>
			<persName><forename type="first">R</forename><surname>Ventura</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Mordec</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Waszczuk</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Lai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Fridlib</surname></persName>
		</author>
		<idno type="DOI">10.1038/nchembio.362</idno>
		<idno>doi: 10.1038/nchembio.362</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="449" to="456" />
			<date type="published" when="2010">2015. 2010</date>
		</imprint>
	</monogr>
	<note>EBioMedicine</note>
</biblStruct>

<biblStruct xml:id="b111">
	<analytic>
		<title level="a" type="main">Acyl protein thioesterase inhibitors as probes of dynamic S-palmitoylation</title>
		<author>
			<persName><forename type="first">D</forename><surname>Davda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><forename type="middle">R</forename><surname>Martin</surname></persName>
		</author>
		<idno type="DOI">10.1039/C3MD00333G</idno>
	</analytic>
	<monogr>
		<title level="j">Medchemcomm</title>
		<imprint>
			<biblScope unit="volume">5</biblScope>
			<biblScope unit="page" from="268" to="276" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b112">
	<analytic>
		<title level="a" type="main">ZDHHC7mediated S-palmitoylation of Scribble regulates cell polarity</title>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Deran</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><forename type="middle">K</forename><surname>Jarugumilli</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">S</forename><surname>Brooks</surname></persName>
		</author>
		<idno type="DOI">10.1038/nchembio.2119</idno>
	</analytic>
	<monogr>
		<title level="j">Nat Chem Biol</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="page" from="686" to="693" />
			<date type="published" when="2016">2016</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b113">
	<analytic>
		<title level="a" type="main">Palmitoylation-dependent activation of MC1R prevents melanomagenesis</title>
		<author>
			<persName><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Zhu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Yin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Han</surname></persName>
		</author>
		<author>
			<persName><forename type="first">B</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature23887</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">549</biblScope>
			<biblScope unit="page" from="399" to="403" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b114">
	<analytic>
		<title level="a" type="main">APT2 inhibition restores scribble localization and S-palmitoylation in snailtransformed cells</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Hernandez</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><surname>Davda</surname></persName>
		</author>
		<author>
			<persName><forename type="first">See</forename><surname>Cheung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Kit</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">D</forename><surname>Majmudar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Won</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Gang</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.chembiol.2016.12.007</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Chem Biol</title>
		<imprint>
			<biblScope unit="volume">24</biblScope>
			<biblScope unit="page" from="87" to="97" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b115">
	<analytic>
		<title level="a" type="main">Tumour suppression by blocking palmitoylation</title>
		<author>
			<persName><forename type="first">S</forename><surname>Lefrancois</surname></persName>
		</author>
		<idno type="DOI">10.1038/s41551-019-0383-6</idno>
	</analytic>
	<monogr>
		<title level="j">Nat BioMed Eng</title>
		<imprint>
			<biblScope unit="volume">3</biblScope>
			<biblScope unit="page" from="255" to="256" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b116">
	<analytic>
		<title level="a" type="main">Functional importance of palmitoyl protein thioesterase 1 (PPT1) expression by Sertoli cells in mediating cholesterol metabolism and maintenance of sperm quality</title>
		<author>
			<persName><forename type="first">W</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><surname>Qian</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1002/mrd.23173</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Reprod Dev</title>
		<imprint>
			<biblScope unit="volume">86</biblScope>
			<biblScope unit="page" from="984" to="998" />
			<date type="published" when="2019">2019</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b117">
	<analytic>
		<title level="a" type="main">Palmitoyl-protein thioesterase-1 deficiency mediates the activation of the unfolded protein response and neuronal apoptosis in INCL</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">C</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">J</forename><surname>Kim</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">S</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">C</forename><surname>Tsai</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Xu</surname></persName>
		</author>
		<idno type="DOI">10.1093/hmg/ddi451</idno>
	</analytic>
	<monogr>
		<title level="j">Hum Mol Genet</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="337" to="346" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b118">
	<analytic>
		<title level="a" type="main">A unified approach to targeting the lysosome&apos;s degradative and growth signaling roles</title>
		<author>
			<persName><forename type="first">V</forename><forename type="middle">W</forename><surname>Rebecca</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">C</forename><surname>Nicastri</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Mclaughlin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Fennelly</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Mcafee</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Ronghe</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-17-0741</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="1266" to="1283" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b119">
	<analytic>
		<title level="a" type="main">PPT1 inhibition enhances the antitumor activity of anti-PD-1 antibody in melanoma</title>
		<author>
			<persName><forename type="first">G</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><surname>Ojha</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Noguera-Ortega</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Rebecca</forename><surname>Vw</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Attanasio</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Liu</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci.insight.133225</idno>
	</analytic>
	<monogr>
		<title level="j">JCI Insight</title>
		<imprint>
			<biblScope unit="page">5</biblScope>
			<date type="published" when="2020">2020</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b120">
	<analytic>
		<title level="a" type="main">The importance of claudin-7 palmitoylation on membrane subdomain localization and metastasis-promoting activities</title>
		<author>
			<persName><forename type="first">S</forename><surname>Heiler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Mu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Zoller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Thuma</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12964-015-0105-y</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Commun Signal</title>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="page">29</biblScope>
			<date type="published" when="2015">2015</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b121">
	<analytic>
		<title level="a" type="main">Protein palmitoylation in cancer: molecular functions and therapeutic potential</title>
		<author>
			<persName><forename type="first">B</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Hao</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Liang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Kong</surname></persName>
		</author>
		<idno type="DOI">10.1002/1878-0261.13308</idno>
	</analytic>
	<monogr>
		<title level="j">Mol Oncol</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<biblScope unit="page" from="3" to="26" />
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b122">
	<analytic>
		<title level="a" type="main">Protein acyltransferase DHHC3 regulates breast tumor growth, oxidative stress, and senescence</title>
		<author>
			<persName><forename type="first">C</forename><surname>Sharma</surname></persName>
		</author>
		<author>
			<persName><forename type="first">H</forename><forename type="middle">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Q</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Knoblich</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">S</forename><surname>Reisenbichler</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">L</forename><surname>Richardson</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.Can-17-1536</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Res</title>
		<imprint>
			<biblScope unit="volume">77</biblScope>
			<biblScope unit="page" from="6880" to="6890" />
			<date type="published" when="2017">2017</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b123">
	<analytic>
		<title level="a" type="main">Palmitoyl transferases act as novel drug targets for pancreatic cancer</title>
		<author>
			<persName><forename type="first">Z</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Z</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName><forename type="first">X</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Huang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12967-023-04098-3</idno>
	</analytic>
	<monogr>
		<title level="j">J Trans Med</title>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="page">249</biblScope>
			<date type="published" when="2023">2023</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
